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Abstract 
RNA sequences are expected to be identical to the DNA template. However, some RNA 
processing steps, such as RNA editing, can lead to differences in the RNA sequence that affect 
the fate of the RNA transcripts or the resultant proteins. My thesis focuses on the regulation of 
the canonical A-to-G editing and non-canonical RNA-DNA sequence Differences (RDD). My work 
contributed to the identification of RDDs throughout the human transcriptome. We identified 
all 12 types of single base differences across multiple individuals and various tissue types. We 
also detected peptides matching the RDD-encoded sequences suggesting that RDDs are 
translated into proteins. In subsequent work, we found that the non-canonical RDDs are found 
in nascent RNA. Through the use of nuclear run-on assays, we found that RDD occurs within 
seconds of exiting the RNA polymerase complex.  
Chapters 4 and 5 discuss my study of canonical A-to-G editing mediated by Adenosine 
Deaminase Acting on RNA (ADAR). First, we found that A-to-G editing levels differ across 
individuals. I searched for and identified genetic variants whose alleles are associated with 
editing levels of sites in the same gene. These data demonstrate that ADAR editing is cis 
regulated and can lead to individual variability in editing levels. Furthermore, by utilizing 
individual variability in editing and studying the relationship between editing sites, I learned 
how ADAR edits multiple sites in a given transcript. My data support a model where ADAR edits 
multiple sites along one side of a double-stranded RNA structure. To learn about the biological 
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significance of RNA editing, I focused on endoplasmic reticulum (ER) stress. I found that editing 
levels change following ER stress suggesting that these RNA processing steps play a role in the 
ER stress response. Together, this work sheds light on the regulation of RNA editing and RDDs in 
the human transcriptome and aids in the understanding of how these processes may play a role 
in cellular response to stress. 
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Chapter 1: Introduction 
 
 RNA is generally assumed to be a copy of its DNA template, but there are many 
processes that modify RNA transcripts. These modifications give rise to a number of unique 
proteins from just one genomic locus.  
 One example of increased variability in proteins comes from RNA splicing. For many 
years, it was assumed that transcript splicing was constant and always occurred at the same 
position. However, over the last decade, it has become clear that many genes show alternative 
splicing. In fact, it is estimated that over 90% of human genes with multiple exons show 
alternative splicing (Pan et al., 2008, Wang et al., 2008). There are many examples where each 
isoform has been shown to perform different tasks. For example, there are eight isoforms of 
CASP8, a gene involved in apoptosis, where some of the isoforms produce proteins that have an 
anti-apoptotic function and the others produce proteins that are pro-apoptotic (Himeji et al., 
2002). This example, as well as many others, demonstrates the importance of protein diversity 
and how changes to RNA transcripts can impact the cell. 
 In addition to splicing, the RNA transcript goes through numerous processing steps 
before it is translated into protein or degraded. Some of these steps can affect the RNA 
sequence such that it no longer matches the corresponding DNA sequence. For example, RNA 
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editing modifies the sequence content of the RNA transcripts and can change the protein 
coding sequences or regulatory sequences.  
Identification of RNA editing 
The first evidence of RNA editing was seen in the mitochondria of trypanosomes in the 
coxII gene (Benne et al., 1986). The coxII gene is found in many species. It was found that DNA 
of the sequence of coxII gene in T. brucei was very different than the sequences found in other 
organisms and was not predicted to form a functional protein (Hensgens et al., 1984, Payne et 
al., 1985). However, when Benne et al studied the mRNA sequence of coxII it was found that 
uracils were being added into the RNA transcript that could not be found in the corresponding 
DNA sequence. These uracils restored the functional capacity of the transcript to make the coxII 
protein.  
Following this characterization of coxII, other examples of uracil additions and deletions 
were found in trypanosomes demonstrating that this is a widespread phenomenon. Similar to 
the coxII gene, insertion and deletion of uracils in COIII (Feagin et al., 1988a) and MURF3 (Shaw 
et al., 1989) restored the sequence that in other organisms would result in a functional protein. 
This suggested that RNA editing may be a way to bypass any detrimental mutations in the DNA 
sequence. With further study, it was found that some transcripts are highly edited and are 
almost unrecognizable in their DNA form (Feagin et al., 1988a, Maslov et al., 1992). In addition 
to restoring conserved sequences, in some cases, multiple species will use RNA editing at 
various positions in the RNA sequence to result in the same functional amino acid sequence 
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(Feagin et al., 1988b, Shaw et al., 1988). For example, two kinetoplastid species have been 
shown to edit COIII in different patterns to result in a protein sequence that only differs by one 
residue (Shaw et al. 1988). These results demonstrate that RNA editing is a way to maintain a 
functional protein. 
The mechanism of RNA editing in trypanosomes was elucidated by Blum et al (Blum et 
al., 1990) by the identification of guide RNAs (gRNA). Guide RNAs are encoded on minicircles in 
the mitochondria of trypanosomes. The gRNAs contain an anchor at the 5’ end that is 
complementary to the mRNA transcript. The middle region of the gRNA contains the sequence 
complementary to the processed mRNA such that the uracil will be added opposite any 
adenosine in the gRNA (Blum et al., 1990, Seiwert et al., 1996, Leung and Koslowsky, 1999). In 
this way, the sequence of the guide RNA directs the insertions or deletions of uracil throughout 
the target mRNA transcript. 
The gRNAs are templates for the editing. The necessary enzymes are found in a complex 
termed the RNA Editing Core Complex (RECC). There are different forms of the RECC that can 
lead to insertion or deletion of uracil residues. The complex must include a terminal uridylyl 
transferase (TUTase) to add uracil residues or an exonuclease to delete uracil residues, 
scaffolding proteins and an RNA ligase (Rusché et al., 1997, Carnes et al., 2005, Stuart et al., 
2005, Trotter et al., 2005, Aphasizhev and Aphasizheva, 2008). First, an endonuclease cleaves at 
the mismatched base. Next, a terminal uridylyl transferase (TUTase) adds uracil residues which 
then need to be trimmed back to match the gRNA sequence by a 3’ to 5’ exonuclease. Finally an 
RNA ligase puts the cleaved fragments back together (Piller et al., 1995, Aphasizhev et al., 
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2002). Though this form of editing has been demonstrated in several kinetoplastids, different 
types of editing have been found in other organisms. 
RNA Editing in Plants 
A few years after the identification of RNA editing in the mitochondria of trypanosomes, 
another type of RNA editing was identified in the mitochondria and plastids of plants (Covello 
and Gray, 1989, Gualberto et al., 1989, Hiesel et al., 1989, Hoch et al., 1991). The type of editing 
found in these organelles was a single-base change leading to a C-to-U or U-to-C difference 
between the DNA and the corresponding mRNA sequence. 
Similar to the editing found in trypanosomes, editing in plants is necessary for 
expression of functional proteins. This can occur through modification of the amino acid 
sequence (Bock et al., 1994, Sasaki et al., 2001) or changing a start (Hoch et al., 1991) or stop 
codon (Wintz and Hanson, 1991). RNA editing in plants is mediated through a family of enzymes 
containing a pentatricopeptide repeat (PPR) motif (Kotera et al., 2005). These proteins had 
previously been shown to be involved in other types of RNA processing, such as splicing 
(Delannoy et al., 2007, Schmitz-Linneweber and Small, 2008). The PPR-containing enzymes 
recognize specific regions of the target mRNA (Bock et al., 1996, Chaudhuri and Maliga, 1996, 
Okuda et al., 2006). The PPR region of these family members is variable and many plants 
contain hundreds of PPR proteins (Lurin et al., 2004). Due to the large number of PPR-
containing proteins and their variable RNA binding domains, it has been suggested that each 
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protein may bind to only a few targets leading to the wide variety of target sites. Questions still 
remain on the identity of the protein able to create the C-to-U or the rare U-to-C edits.  
RNA editing in plants is sometimes found in every transcript (Lu and Hanson, 1994), but 
many times, editing is variable. For example, nad3 contains multiple editing sites, none of which 
are edited in every transcript (Schuster et al., 1990). This suggests that there may be another 
reason for RNA editing besides reverting a specific mutation back to the ancestral form of the 
protein. It is possible that RNA editing may be a way to introduce various forms of an mRNA 
transcript to either affect the resulting proteins or regulate expression of the gene (Lu et al., 
1996, Phreaner et al., 1996). 
RNA editing in organisms as diverse as trypanosomes and plants suggests that RNA 
editing plays a key role in maintaining protein function. It may also provide variability in the 
mRNA transcripts to encode multiple functional gene products. 
Identification of RNA Editing in Mammals 
While editing was being identified in trypanosomes, other scientists were noting a 
strange discrepancy in apolipoprotein B (APOB) which leads to two forms of the protein, B-48 
and B-100. Apolipoprotein B has been a protein of interest for decades due to its involvement 
in cholesterol metabolism and uptake. In the early 80s it was found that APOB came in two 
different forms, B-48 and B-100 (Kane et al., 1980, Wu and Windmueller, 1981). Though 
cholesterol was very well studied, many groups struggled to isolate the two unique forms of the 
APOB protein due to their hydrophobic nature. Once the two forms were identified, it was 
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necessary to determine whether they were from the same gene and RNA transcript. This 
proved to be a difficult question to answer due to the limitations of mass spectrometry and 
sequencing. Some argued that they must be proteins resulting from different gene loci because 
there were diseases that caused only one form to be expressed (Malloy et al., 1981). However, 
there was a single mutation that could be traced to both forms (Young et al., 1986). With the 
use of specific antibodies, researchers were able to identify large homologies between the two 
forms of APOB supporting the idea that both forms resulted from a single gene (Marcel et al., 
1982, Hospattankar et al., 1986). 
The next hurdle was to determine how the two forms could be made from a single gene 
and why expression of the two forms was tissue specific. In humans, B-48 was found in the 
small intestine while B-100 was found in liver. Multiple groups found that these two proteins 
were not only produced from a single gene but that there was a single, post-transcriptional 
editing process that lead to a premature stop codon (CAA to UAA) (Chen et al., 1987, Powell et 
al., 1987, Lau et al., 1991). Then in 1993, Apolipoprotein B Editing Catalytic subunit 1 (APOBEC) 
was found to be responsible for deaminating the cytosine to uracil at position 6666 (Teng et al., 
1993). APOBEC, in complex with APOBEC-1 complementation factor (ACF), deaminates the 
specific cytosine using the surrounding sequence as an anchor (Dance et al., 2002).  
APOBEC and APOB are the first enzyme and target pair of RNA editing identified in 
humans. Soon, another form of RNA editing would be found that affects thousands of sites 
throughout the human transcriptome. 
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ADAR RNA Editing 
The identification of trypanosome editing and APOBEC RNA editing opened the doors to 
searching for still further examples of RNA editing. In the late 1980s, a protein family was 
identified in xenopus embryos that would be called adenosine deaminases acting on RNA 
(ADAR) (Bass and Weintraub 1988, Kim et al., 1994). At the time the function of ADAR was not 
clear. It was found that ADAR bound and unwound double-stranded RNA. Further investigation 
found that inosine was present in the RNA following ADAR binding (Bass and Weintraub 1988). 
Finally, it was understood that ADAR deaminates the adenosine to inosine which resulted in 
disruption of the double-stranded structure and the unwinding phenomenon that was originally 
found (Wagner et al., 1989). 
There are four different ADAR proteins in humans: ADAR1, ADAR2, ADAR3 and ADAR4. 
ADAR4 is expressed in testes, suggesting that it may play a role in spermatogenesis (Meng et 
al., 1997, Connolly et al., 2005). ADAR3 is expressed in the brain and is not known to be 
catalytically active; however, it may play a role in regulating the activity of ADAR1 and ADAR2 
(Chen et al., 2000). ADAR1 and ADAR2 are expressed in most tissues and can edit many sites 
throughout the transcriptome (Wang et al., 2013). 
ADAR1 and ADAR2 catalyze deamination of adenosines to inosines in double-stranded 
RNA (dsRNA) regions. Inosines base-pair similar to guanosine and so inosines are read by 
translational machinery as a guanosine (Reuter et al., 1999, Bass 2002, Jepson and Reenan, 
2008, Nishikura 2010). Therefore, ADAR enzymes effectively induce an A-to-G difference 
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between the DNA and the corresponding RNA sequence. ADAR enzymes specifically target large 
stretches of dsRNA regions. Studies have shown that RNA structures less than 100 bases long 
show far fewer instances of editing than longer ones (Nishikura et al., 1991). In addition to 
targeting dsRNA regions, ADAR enzymes also use the surrounding sequences to identify their 
target sites. Both ADAR1 and ADAR2 targets show a depletion of guanosine just upstream of 
the editing site, while an enrichment of guanosine just downstream of the editing site (Polson 
and Bass, 1994, Lehmann and Bass, 2000, Eggington et al., 2011).  
One of the best characterized examples of ADAR editing is in the AMPA receptor in 
mammals (Rueter et al., 1995, Yang et al., 1995). The editing of a subunit of the AMPA receptor, 
GluR2, changes the amino acid sequence at two sites, 607 (Q-to-R) and 764 (R-to-G) (Seeburg et 
al., 1998). Editing at site 764 changes the recovery from inactivation of the channel (Lomeli et 
al., 1994). The editing at site 607 (Sommer et al., 1991) influences the conductance of the 
AMPA receptor and is edited to 100% in human adults. The arginine at site 607 decreases 
calcium influx and affects the targeting of the receptors to the neuronal synapses (Sommer et 
al., 1991, Seeburg et al., 1998, Greger et al., 2002). When editing is prevented in mice, seizures 
or death can occur. This further emphasizes the importance of RNA editing in these neuronal 
ion channels (Brusa et al., 1995). A number of examples of ADAR editing affecting ion channel 
function in neurons have been found (Sommer et al., 1991, Köhler et al., 1993, Nutt et al., 1994, 
Paschen and Djuricic, 1994, Paschen et al., 1994, Burns et al., 1997, Bhalla et al., 2004, Ohlson 
et al., 2007). 
9 
 
 
In addition to the editing of ion channels in the brain, recent studies have shown that 
ADAR editing is widespread throughout the transcriptome (Athanasiadis et al., 2004, Levanon 
et al., 2004, Li et al., 2009, Wang et al., 2013, Bazak et al., 2014a, Ramaswami and Li, 2014, 
Sakurai et al., 2014, Ulbricht and Emeson, 2014). The identification of these additional sites has 
led to the characterization of two types of editing: site-selective and promiscuous (Wahlstedt 
and Ohman, 2011). These terms are not well defined and generally describe one or a few sites 
in a given region versus many sites in a region, respectively. The sites commonly found in ion 
channels would be termed site-selective editing sites. On the other hand, numerous transcripts 
show evidence of promiscuous editing. 
Promiscuous editing, or hyper-editing, does not mean that a site is not consistently 
edited but rather that multiple editing sites occur in the same region. This has been found to 
occur in Alu elements in the primate genomes (Ramaswami et al., 2012, Levanon et al., 2004, 
Athanasiadis et al., 2004). Alu elements are abundant, comprising about 10% of the human 
genome (Batzer and Deininger, 2002). Editing sites are often found in genes with multiple Alu 
elements oriented in opposite directions (Athanasiadis et al., 2004). The two opposite Alu 
elements in the transcript can base-pair to make a long dsRNA region. This is then a target of 
ADAR editing (Bazak et al., 2014b). 
The role of editing in non-coding regions is not as clear as the editing that occurs in the 
coding regions of the genes. However, several studies have demonstrated that editing in the 
non-coding regions of a transcript may play an important role in regulating gene expression.  
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One example is the role of editing on mRNA splicing. ADAR2 editing of its own mRNA 
transcript leads to differential splicing by creating a 3’ acceptor site leading to lower expression 
of ADAR2 (Rueter et al., 1999, Feng et al., 2006). Additionally, ADAR-mediated editing was 
shown to affect splicing of other genes, suggesting that this may be a common mechanism of 
controlling gene expression (Lev-Maor et al., 2007).  
RNA editing has also been shown to occur within microRNAs (miRNAs) (Luciano et al., 
2004) and affect their miRNA processing. For example, editing of the precursor of miRNA-142 
leads to a decrease in the expression of the mature miRNA by affecting cleavage of the 
transcript by Drosha or Dicer (Chawla and Sokol, 2014, Yang et al., 2006). Some studies have 
shown that ADAR-mediated editing can result in mature miRNAs with different targets due to 
changes to the seed sequence (Kawahara et al., 2008, Alon et al., 2012, Kume et al., 2014). 
Related studies have also shown that ADAR editing can interfere with the related siRNA 
pathway (Wu et al., 2011). 
While the previous two examples demonstrate how an adenosine to guanosine change 
in sequence can influence protein binding, inosine, itself, can be a target for RNA binding 
proteins. First, inosine can allow for sequestration of the mRNA transcript in the nucleus by a 
complex containing an inosine-specific binding protein NURSA, a splicing factor PSF and a 
nuclear matrix protein (Zhang and Carmichael 2001). Additionally, inosine can lead to 
recruitment of a factor involved in the RNA-induced silencing complex leading to degradation of 
the transcript (Scadden and Smith 2001, Scadden 2005, Scadden and O’Connell, 2005). Through 
these, and likely additional, pathways, RNA editing can affect the regulation of gene expression. 
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Non-canonical editing 
While APOBEC and ADAR can induce C-to-U and A-to-I differences between DNA and 
corresponding RNA sequence, respectively, some studies have described genes that have other 
types of single-base differences in sequence. For example, Sharma et al describe a U-to-C 
difference in the Wilms’ tumor gene (WT1) (Sharma et al., 1994). WT1 acts as a transcriptional 
regulator and loss of WT1 is associated with Wilms’ tumor and childhood malignancies in the 
kidney (Call et al., 1990, Gessler et al., 1990). This group found that a U-to-C difference within 
the coding region of the gene that changes a leucine to a proline residue. They found that the 
proline form of the protein is less efficient at repressing a target promoter (EGR1) than the 
DNA-encoded leucine form. This example demonstrates that other base differences, in addition 
to the canonical A-to-G and C-to-U, can occur between the DNA and RNA sequence and that 
they may play a role in protein function. 
A recent study identified more single base differences in WT1 including a G-to-A site 
(Niavarani et al., 2015). Through knock-down and over-expression, they found that APOBEC3A 
is responsible for the G-to-A difference. APOBEC3A is a part of the APOBEC family but has 
mostly been known to target viral DNA as a part of the immune response. This finding 
demonstrates that the other members of the APOBEC family may also play a role in the other 
types of non-canonical RNA editing in human cells. 
Other examples of non-canonical editing can be found in hnRNP K which contains a G-
to-A difference, TPH2 that contains multiple differences including A-to-G, C-to-U, T-to-C and G-
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to-A, and β amyloid precursor protein and ubiquitin-B protein which contain frameshift RDDs 
(van Leeuwen et al., 1998, Klimek-Tomczak et al., 2006, Grohmann et al., 2010). The 
mechanisms that mediate these differences have not yet been elucidated. A few years ago, we 
showed (described in Chapter 2) that RNA-DNA sequence Differences (RDD) can be found 
transcriptome-wide. 
Endoplasmic Reticulum Stress 
 During my thesis work, I wondered how RNA editing can be influenced by 
environmental stress. To answer this question, I studied RNA editing in response to 
endoplasmic reticulum (ER) stress (chapter 6). The endoplasmic reticulum is a membrane-
bound organelle that is split into two parts: smooth ER that plays a role in lipid metabolism and 
the rough ER that modifies and transports proteins. ER stress occurs when there are excess 
misfolded proteins in the cell.  
 The ER stress response is complex and can determine whether a cell will return to 
homeostatic conditions or commit to apoptosis. When misfolded proteins accumulate in the 
cell they recruit protein chaperones such as BiP through hydrophobic interactions. When BiP is 
recruited to the misfolded proteins, it is released from three membrane-bound proteins 
responsible for triggering the ER stress response: IRE1, PERK and ATF6 (Bertolotti et al., 2000).  
 IRE1, Inositol-Requiring Enzyme 1, dimerizes and transphosphorylates after release of 
BiP (Bertolotti et al., 2000). This activation then allows IRE1 to splice the mRNA of XBP1, X-box 
Binding Protein 1, to XBP1s which is translated into an active transcription factor (Yoshida et al., 
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2001, Calfon et al., 2002). XBP1s promotes the expression of many proteins involved in the ER 
stress response, such as BiP, the protein chaperone, and EDEM which is involved in ER-
associated decay to remove misfolded proteins (Kaneko and Nomura, 2003, Lee et al., 2003). 
 PERK, Pancreatic EIF2α Kinase, like IRE1 oligomerizes and transphosphorylates following 
release of BiP (Bertolotti et al., 2000). PERK then inactivates eIF2α by phosphorylation. eIF2α is 
a eukaryotic translational initiation factor. Through phosphorylation of eIF2α, PERK attenuates 
translation in the cell to attenuate the accumulation of misfolded proteins. Though most 
proteins cannot be translated under these conditions, certain proteins such as ATF4 are 
upregulated. ATF4 is a transcription factor that upregulates genes involved in the induction of 
apoptosis, such as CHOP, C/EBP Homology Protein (Harding et al., 2003).  
 Finally, ATF6 is activated following release of BiP by transport to the Golgi apparatus 
where it is proteolytically cleaved. The cytoplasmic portion of ATF6 can then act as a 
transcription factor to regulate ER stress-related genes (Ye et al., 2000, Chen et al., 2002, Shen 
and Prywes, 2004, Shen et al., 2005). ATF6 upregulates protein chaperones, such as BiP and 
GRP94 (Yoshida et al., 1998). 
 Together these three pathways lead to a complex ER stress response including induction 
of proteins involved in reestablishing homeostasis, such as the protein chaperones, or induction 
of apoptosis mediators, such as CHOP. IRE1 and ATF6 are inactivated by feedback loops before 
PERK. When ER stress continues, only PERK remains active, thereby leading to apoptosis (Lin et 
al., 2007).  
14 
 
 
ER stress occurs under many conditions such as rapid growth in cancer cells, in the β-
cells of the pancreas that are making large amounts of insulin, or in B-cells that make large 
amounts of antibody proteins (Ma and Hendershot, 2004, Lee et al., 2005, Zhang et al., 2005). 
ER stress can lead to diseases such as diabetes. When a β-cell undergoes excess ER stress, it 
dies and loss of these β-cells can lead to diabetes (Oyadomari et al., 2002). We study editing 
under ER stress conditions because it may help us to understand these various diseases. 
My Thesis Summary 
 My work in canonical RNA editing and RNA-DNA sequence Differences, broadly defined 
as single-base differences between the DNA and RNA sequences that cannot be explained by 
canonical editing mechanisms, describes the importance of these RNA processing steps in RNA 
regulation and cellular response to stress. 
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Abstract 
The transmission of information from DNA to RNA is a critical process. We compared 
RNA sequences from human B cells of 27 individuals to the corresponding DNA sequences from 
the same individuals and uncovered more than 10,000 exonic sites where the RNA sequences 
do not match that of the DNA. All 12 possible categories of discordances were observed. These 
differences were nonrandom as many sites were found in multiple individuals and in different 
cell types including primary skin cells and brain tissues. Using mass spectrometry, we detected 
peptides that are translated from the discordant RNA sequences and thus do not correspond 
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exactly to the DNA sequences. These widespread RNA-DNA differences in the human 
transcriptome provide a yet unexplored aspect of genome variation. 
Introduction 
DNA carries genetic information that is passed onto messenger RNA (mRNA) and 
proteins that perform cellular functions and it is assumed that the sequence of mRNA reflects 
that of the DNA. This assumed precision is important since mRNA serves as the template for 
protein synthesis. Hence, genetic studies have mostly focused on DNA sequence polymorphism 
as the basis of individual differences in disease susceptibility. Studies of mRNA and proteins 
analyze their expression and not sequence differences among individuals. 
There are, however, known exceptions to the one-to-one relationship between DNA and 
mRNA sequences. These include errors in transcription(Libby and Gallant, 1992, Sydow and 
Cramer, 2009) and RNA-DNA differences that result from RNA editing(Chen et al., 1987, Rowell 
et al., 1987, Bass and Weintraub, 1988, Li et al., 2009, Athanasiadis et al., 2004). Errors are rare 
since proof-reading and repair mechanisms ensure the fidelity of transcription(Thomas et al., 
1998, Wang et al., 2009, Zenkin et al., 2006). RNA editing is carried out by enzymes that target 
mRNA post-transcriptionally: ADARs that deaminate adenosine to inosine which is then 
recognized by the translation machineries as a guanosine (A-to-G), and APOBECs which edit 
cytidine to uridine (C-to-U). Previously, sequence comparisons and computational predictions 
have identified many A-to-G editing sites(Li et al., 2009, Athanasiadis et al., 2004, Sakurai et al., 
2010, Nishikura, 2010, Levanon, et al., 2004). In contrast, C-to-U changes are rare; 
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apolipoprotein B is one of a small number of known target genes of human 
APOBEC1(Conticello, 2008, Chester et al., 2000). 
Samples 
We obtained sequences of DNA and RNA samples from immortalized B-cells of 27 
unrelated Centre d’Etude du Polymorphisme Humain (CEPH)(Dausset et al., 1990) individuals, 
who are part of the International HapMap(International HapMap Consortium, 2003, 
International HapMap Consortium, 2005) and the 1000 Genomes(1000 Genomes Project 
Consortium, 2010) Projects. When we compared the DNA and RNA sequences of the same 
individuals, we found 28,766 events at over 10,000 exonic sites that differ between the RNA 
and the corresponding DNA sequences. Each of these differences were observed in at least two 
individuals; many of these were seen in B-cells, as well as in primary skin cells and brain tissues 
from a separate set of individuals and in expressed sequence tags from cDNA libraries of 
various cell types. About 43% of the differences are transversions and therefore cannot be the 
result of typical deaminase-mediated RNA editing. By mass spectrometry, we also found 
peptide sequences that correspond to the RNA variant sequences, but not the DNA sequences, 
suggesting that the RNA forms are translated into proteins.  
We compared the DNA and RNA sequences from B-cells of 27 unrelated CEPH 
individuals (Table S2.1). We chose these samples because much information is available on 
them including dense DNA genotypes obtained using different technologies(Cann, 1992, Matise 
et al., 2003). The genomes of B-cells from the CEPH collection are stable as evidenced by 
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Mendelian inheritance of genetic loci that allowed the construction of microsatellite- to SNP-
based human genetic maps(Cann, 1992, Matise et al., 2003). More recently the International 
HapMap Consortium(International HapMap Consortium, 2003, International HapMap 
Consortium, 2005) obtained millions of SNP genotypes and the 1000 Genomes Project(1000 
Genomes Project Consortium, 2010) sequenced the DNA of these individuals. Comparison of 
sequence data from these two projects showed high concordance (~99%). Here, we used the 
DNA genotypes and sequences from the two projects for our analyses. First, we considered 
sites that are monomorphic in the human genome. A monomorphic site is one where there is 
no evidence for sequence variation at that locus in dbSNP, the HapMap and the 1000 Genomes 
Projects. Different studies have analyzed these 27 and hundreds of additional individuals for 
DNA variants; thus if a site has not been identified as polymorphic, most likely all individuals 
have the same sequences at these sites. But to be certain, for these sites in the 27 individuals, 
we compared their DNA sequences from the 1000 Genomes Project with the sequences of the 
human reference genome and carried out traditional Sanger sequencing(Sanger et al., 1977). To 
be included in our analysis, we required that each site to be covered by at least four reads in 
the 1000 Genomes Project and that the sequences from 1000 Genomes are the same as the 
reference genome. To ensure the integrity of the aliquots of B-cells we used for analyses, we 
carried out Sanger sequencing of their DNA and found perfect concordance of sequences with 
data from 1000 Genomes (thus also the reference genome sequences) (Table S2.2). Second, we 
considered SNPs. For each individual, a SNP locus is included only if it is homozygous and the 
HapMap as well as the 1000 Genomes projects reported the same sequence. We have high 
confidence in those sequences since despite using different technologies (microarray-based 
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genotyping in HapMap and high-throughput sequencing in 1000 Genomes), identical sequences 
were obtained in the two projects.  
We sequenced the RNA of B-cells from the same 27 individuals using high-throughput 
sequencing technology from Illumina (Bentley et al., 2008). The resulting RNA sequence reads 
were mapped to the Gencode genes(Harrow et al., 2006) in the reference human genome. In 
total, we generated ~1.1 billion reads of 50 base pairs (bp) (~41 million reads and 2 Gb 
sequence per individual), of which ~69% of the reads mapped uniquely to the transcriptome 
(see Methods in Supporting Material). To be confident of the base calls, for each individual, we 
focused our analysis on high quality reads (quality score ≥ 25) and sites that are covered by at 
least 10 uniquely mapped reads. Another study (Montgomery et al., 2010) had carried out RNA-
Sequencing of the same individuals but at a lower coverage; at these sites we compared our 
sequences with those from their study, the concordance rate of the sequences is >99.5%. This is 
reassuring given that the samples were prepared and sequenced in different laboratories. 
Differences between RNA and corresponding DNA sequences 
For each of 27 individuals, we compared the mRNA sequences from B-cells with the 
corresponding DNA sequences (Fig. S2.1). The comparison revealed many sites where the 
mRNA sequences differ from the corresponding DNA sequences of the same individual. To 
ensure that these are actual differences and to minimize the chance of sequencing errors, we 
required that at least 10% of the reads covering a site to be different from the DNA sequence 
and at least two individuals show the same RNA-DNA difference at the site. We call each 
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occurrence of a difference between RNA and DNA sequences, an event, and the chromosomal 
location where such a difference occurs, a site. Each person can contribute an event to the site, 
thus there could be multiple events at a site. 
Among our 27 subjects, we identified 28,766 events where the RNA sequences do not 
match those of the corresponding DNA sequences. These events are found in 10,210 exonic 
sites (Table S2.10) in the human genome and reside in 4,741 known genes (36% of 13,214 
genes that are covered by 10 or more RNA-Seq reads in at least one part of the gene, in two or 
more individuals). With gene orientation information in Gencode, we observed all 12 possible 
categories of base differences between RNA and its corresponding DNA (Fig. 2.1A). All 12 types 
of differences were found in each of the 27 samples; the relative proportion of each type is 
similar across individuals. There are 6,698 A-to-G events which can be the result of deamination 
by ADAR. There are 1,220 C-to-T differences which can also be mediated by a deaminase. 
However it is important to note that APOBEC1 and its complementation factor A1CF that 
deaminate cytidine are not expressed in our B-cells (FPKM(Trapnell et al., 2010)~0 for both 
genes) thus it is likely that an unknown deaminase or other mechanism is involved. Even for 
relatively well characterized proteins such as APOBEC1, a recent RNA-Seq study of Apobec1-/- 
mice uncovered many previously unknown targets(Rosenberg et al., 2011). In addition, we 
found 12,507 transversions (43%); which cannot result from classic deaminase-mediated 
editing. Since we do not know the mechanism by which these differences between RNA and 
DNA sequences arise, we refer to them as RNA-DNA Differences or RDD. An example of RDD is a 
C-to-A difference on chromosome 12 (at position 54,841,626 bp) in the myosin light chain gene 
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MYL6 where 16 of our subjects have C/C in their DNA but A/C in their RNA sequences. Another 
example is an A-to-C difference on chromosome 6 (at position 44,328,823 bp) in the gene, 
HSP90AB1, that encodes a heat shock protein, where 8 individuals who have homozygous A/A 
DNA genotype but have A/C in their RNA. Additional examples are shown in Table 2.1. These 
sites where RNA sequences differ from the corresponding DNA sequences appear to be non-
random since the identical differences were found in multiple individuals: 8,163 (80.0%) of the 
sites were found in at least 50% of the informative individuals (i.e. with RNA-Seq coverage ≥10 
and DNA-Seq coverage ≥4 at the site). Some sites were found in all or nearly all informative 
individuals. For example, the DNA sequences of all 19 informative individuals at position 
49,369,615 bp of chromosome 3 in the GPX1 gene are G/G whereas their RNA sequences are 
G/A. (The remaining individuals were not included because available data did not meet our 
inclusion criteria; although the data suggest the same RDD in all remaining individuals: G/G in 
DNA, and G/A in RNA). 
RDD in expressed sequence tags 
Computational and experimental validations also upheld these observed RNA-DNA 
differences. First, for 120 sites (10 sites per RDD type; randomly selected and all examples cited 
in this paper; see Tables 2.1 and S2.3), we looked for evidence of RDD in the human EST 
database by BLAST alignment(Altschul et al., 1990) and manual inspection of each result. For 81 
of the 120 sites, we found EST clones that contain the RDD alleles. The numbers of sites found 
in human ESTs are similar across different RDD types (average 67.5%, range: 60 to 90%). 
Second, we examined previously identified A-to-G editing sites (Li et al., 2009). Fourteen of the 
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A-to-G sites that we identified were found in their data despite the fact that different cell types 
were studied. Even the levels of editing at these sites are similar between the two studies (see 
Fig. S2.2). Twelve additional sites were found in both studies but were filtered because they did 
not meet our selection criteria.  
Sanger sequencing of B cells, skin, and brain 
Next, we validated our findings experimentally by Sanger sequencing of both DNA and 
RNA at 12 randomly selected sites in B-cells (2 to 9 individuals/ site), primary skin (foreskin; 8 to 
10 individuals/ site) and brain cortex (6 to 10 individuals/ site). We regrew the B-cells from our 
subjects and extracted DNA and mRNA from the same aliquots of cells. From sequencing the 
paired DNA and RNA samples and analysis of each chromatogram by two individuals 
independently, we confirmed 57 events in 11 sites (see Table 2.2, Fig. S2.3). In EIF2AK2, in all 
the 8 individuals whose samples were sequenced, three sites were found within 10 nucleotides 
(see below). RDD was not found in one site in NDUFC2. Sanger sequencing is not very sensitive 
or quantitative thus we do not expect to validate all sites, especially those with low levels of 
RDD.  
To assess if RDD shows cell type specificity, we looked for evidence of RNA-DNA 
sequence differences using primary human cells. We studied the same sites as above by Sanger 
sequencing of DNA and RNA samples from primary skin fibroblasts and brain (cortex) of a 
separate set of normal individuals (for each site, we examined the DNA and RNA of 6 to 10 
samples per cell type). We identified 55 RDD events in primary skin cells and 62 events in brain 
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cortex (Table 2.2). The results suggest that most sites are shared across cell types (Table 2.2); 
although there are exceptions, for example, an A-to-G difference in EIF2AK2 (chr2: 37,181,512) 
which was only found in B-cells and brain cortex but not in primary skin cells. We also queried 
the EST database for evidence of RDD (Tables 2.1, S2.3). The RNA alleles are seen in a wide 
range of tissues from embryonic stem cells to brain and testis; they are also found in tumors 
such as lung carcinoma and neuroblastoma. 
Proteomic evidence for RDD 
Validation at the sequence level is important but does not address all concerns such as 
the difficulty in aligning sequences that are highly similar and errors introduced by enzymes in 
reverse transcription steps. We believe that such artifacts are unlikely considering the 
consistent patterns across sequencing methods and the fact that we observed all 12 types of 
nucleotide differences. An alternate and independent validation would be to ask whether the 
RNA variants in RDD sites are translated to proteins. To do so, first we searched mass 
spectrometry data from human ovarian cancer cells(Sodek et al., 2008) and leukemic cells for 
putative RDD sites. Since the levels of most RDDs are less than 100%, both DNA and the RDD-
forms of the mRNAs should be available to be translated (from here-on, we refer to mRNAs that 
correspond identically to the DNA sequences as DNA-forms and those that contain a RDD as 
RNA-forms). In the ovarian cancer and leukemic cells, we indeed found examples of proteins 
with peptides encoded by both DNA and RNA forms of mRNA (Table S2.4). Encouraged by the 
search results and cognizant of possible genome instability and thus DNA mutations in cancer 
cells, we carried out mass spectrometry analysis of our B-cells. 
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We analyzed the proteome of our B-cells using liquid chromatography-tandem mass 
spectrometry and detected peptides for 3,217 proteins. Despite advances in mass 
spectrometry, far less than 50% of peptides can be detected in most studies(Michalski et al., 
2011, de Godoy et al., 2006). We identified 327 peptides that cover RDD sites: 299 of them are 
encoded by the DNA-forms and 28 by RNA-forms of RDD containing mRNAs (FDR<1%; Table 
S2.5 and S2.9). For 17 RDD sites, peptides that correspond to both DNA and RNA forms were 
identified (Table 2.3). By BLAST alignment, we ensured that these 28 peptides are unique to the 
genes that contain the RDD sites. In addition, we sequenced the DNA of the B-cells used for 
mass spectrometry and validated that the DNA sequences are the same as the reference 
genome but differ from the RNA sequences and thus do not encode the RNA-forms of the 
peptides (Table S2.2). It is easier to detect more abundant proteins by mass spectrometry; for 
most RDD sites, the unaltered DNA forms are more abundant than variant RNA forms of mRNA 
(see below) thus it is not surprising to find more peptides that corresponds to the DNA rather 
than the RNA sequences. However, the counts of peptides corresponding to the DNA and RNA 
forms of RDD sites should not be taken as a measure of the proportions of DNA versus RNA 
forms of mRNA that are translated because differences in the amino acid sequences of the DNA 
and RNA forms of the peptides affect the ability of mass spectrometry to detect them. In 
addition, when a peptide is not detected, it does not mean that it is absent from the proteome, 
it could be result of sampling.  
The proteomic data provide an independent validation that mRNA sequences are not 
always identical to DNA sequences, and demonstrate that RNA-forms of genes are translated to 
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proteins. They also show that there are peptides in human cells that are not exactly encoded by 
the DNA sequences. An example of a protein variant that results from RDD is RPL28 (T-to-A, 
chr19: 60,590,467). The RDD led to a loss of a STOP codon. We identified peptides 
corresponding to the 55 amino acid extension of RPL28 protein in the ovarian cancer cells and 
in our B-cells (Fig. 2.2). Previously identified cases of RNA editing leading to proteins not 
encoded by genomic DNA, such as the apolipoprotein B(Chen et al., 1987, Powell et al., 1987), 
serotonin and glutamate receptors(Burns et al., 1997, Lomeli et al., 1994, Maas et al., 2001) in 
humans and plant ribosomal protein S12(Phreaner et al., 1996), also support our hypothesis 
that RDD leads to protein isoforms that do not correspond to the DNA sequences of the 
encoding genes. 
Individual variation in abundance of RDD 
Using our selection criteria, we found that in each person among the Gencode genes, 
there are on average 1,065 exonic events that differ in the RNA and DNA sequences. But the 
number of events varied among individuals (range: 282 to 1,863) by up to 6-fold across our 27 
subjects (Fig. 2.1B). The degree of sequence coverage and sequencing errors in DNA or RNA 
samples do not explain these individual differences(Supporting Material). Thus there is likely a 
biological basis for the individual variation in the number of editing and RDD events. We found 
no significant correlation between ADAR expression with the number of RDDs or the numbers 
of A-to-G events (P>0.5). Thus, either ADAR expression does not affect the number of editing or 
RDD events, or our sample size is not sufficient to detect the correlation. 
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Characteristics of RDD sites 
The 10,210 sites which showed RNA and DNA sequence differences are not evenly 
distributed across the genome: chromosome 19 has the most whereas chromosome 13 has the 
fewest number of sites. This pattern is observed after correction for differences in size and 
gene density among chromosomes. RDD sites are significantly (P<10-10) enriched in genes that 
play a role in helicase activity, protein and nucleotide binding (Table S2.6). 
We also noted that the 10,210 sites which showed RNA and DNA sequence differences 
are not evenly distributed within genes. About 44% (4,453 sites) of them are located in coding 
exons (10% were found in the last exons), 4% (386 sites) are in the 5’ UTRs, and 39% (3,977 
sites) are in the 3’ UTRs (see Table S2.7, those remaining cannot be classified because of 
differences in gene structures across isoforms). The results suggest that there are more sites in 
the 3’ ends than the 5’ ends of genes; a pattern that was also observed in deamination-
mediated RNA editing(Rosenberg et al., 2011, Hundley et al., 2008). Seventy-one percent of the 
coding sites result in non-synonymous amino acid changes, including 2.1% that lead to the gain 
or loss of a stop codon if translated into proteins. Relative to other structural features in genes, 
we found 4% of RDD sites are within 2 nucleotides of exon borders and 5% are within 30 
nucleotides of poly(A) signals (Table S2.7). Among RDD types, the numbers of sites near splice 
junctions are quite similar but the numbers near poly(A) sites are more different. C-to-A and G-
to-A differences are found more often near poly(A) sites.  
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Sites also tended to cluster; for example, 2,613 sites (26%) are within 25 bp, and 1,059 
sites (10%) are adjacent to each other. Statistical analysis using a runs test supports that the 
locations of the sites are not random (median P = 0.22). We did not find obvious patterns or 
associations with motifs shared across the sites, except for the A-to-G and A-to-C differences 
that show a preference for a cytidine 5’ to the adenosine; as previously observed in ADAR 
mediated A-to-G changes(Athanasiadis et al., 2004, Maas et al., 2001). 
RDD levels 
We examined the percentage of mRNAs that differs in sequence from the corresponding 
DNA. For each site to determine the RDD level, we counted the number of reads with a 
different nucleotide from that in the corresponding DNA sequence. The distribution of the level 
is bimodal (Fig. 2.1C); the average level is 20% (median = 13%). However, for some sites, RDD 
was detected in nearly 100% of the RNA sequences such as the A-to-C difference in the gene 
that encodes an mRNA decapping enzyme, DCP1A (chr3:53297343). This level is correlated with 
the frequency and types of RNA-DNA differences. Sites found in more than 50% of the 
informative individuals tend to have higher levels of RNA editing or RDD than other sites (P < 
10-5; Fig. S2.5). The levels also differ across individuals. For example at a G-to-A site in the gene 
RHOT1, which encodes a RAS protein that plays a role in mitochondrial trafficking 
(chr17:27526465), in one person, the level was 90% while in another person, it was only 18%. 
We identified 437 sites with 10 or more informative individuals where the individuals with the 
highest levels and the lowest levels differ by 2 fold or more (range: 2 to 8.6 fold). 
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Conclusions 
We have uncovered thousands of exonic sites where the RNA sequences do not match 
those of the DNA sequences; including transitions and transversions. These findings challenge 
the long-standing belief that in the same individuals, DNA and RNA sequences are nearly 
identical. To increase the confidence in our results, we obtained the DNA, RNA and protein 
sequences from different individuals and cell types using a range of technologies (Fig. S2.1b). 
The samples included cell lines and primary cells from healthy individuals and tumors. We used 
data from public resources such as EST databases, The HapMap and 1000 Genomes Projects as 
well as those that we generated with traditional Sanger sequencing, high-throughput 
sequencing technologies and mass spectrometry. Table 2.4 showed the DNA, RNA and peptide 
sequences at 15 confirmed sites which illustrate that the RNA and peptide sequences are the 
same but differ from the corresponding DNA sequences. The results support our observation 
that in an individual, DNA and RNA sequences from the same cells are not always identical and 
some of the variant RNA sequences are translated into proteins. The consistent pattern of the 
observations suggests that the RDDs have biological significance and are not just “noise.” At 
nearly all RDD sites, we observed only one RDD type across cell types and in different 
individuals. If the DNA sequence is A/A, and the RNA is A/C in one sample, in other samples, we 
see the same A-to-C difference, but not other types of differences. These results suggest that 
there are unknown aspects of transcription and/or post-transcriptional processing of RNA. 
These differences may now be studied along with those in other genomes and organisms such 
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as the mitochondrial genomes of trypanosomes and chloroplasts of plants, where RNA editing 
and modifications are relatively common(Phreaner et al., 1996, Hundley et al., 2008). 
The underlying mechanisms for these events are largely unknown. For most of the 
cases, we do not know yet whether a different base was incorporated into the RNA during 
transcription or if these events occur post-transcriptionally. About 23% of the sites are A-to-G 
differences; some of these are likely mediated by ADAR, but other, currently unknown, 
mechanisms can be involved. If it is a co-transcriptional process, then the signal can be in the 
DNA or the RNA such as secondary structures or modified nucleotides. In addition, as some of 
the RDDs are found near splice and poly(A) sites; it is possible that this may be a facet of 
systematic RNA processing steps such as splicing and cleavage(Rueter et al., 1995, Rueter et al., 
1999). 
Our findings supplement previous studies demonstrating RNA-DNA differences in the 
human genome, and show that these differences go beyond A-to-G transition. These findings 
impact our understanding of genetic variation; in addition to DNA sequence variation, we 
identify individual variation in RNA sequences. For monomorphic DNA sequences that show 
RDD there is an overall increase in genetic variation. Thus, this variation contributes not only to 
individual variation in gene expression but also diversifies the proteome since some identified 
sites lead to nonsynonymous amino acid changes. We speculate that this RNA sequence 
variation likely affects disease susceptibility and manifestations. To date, mapping studies have 
focused on identifying DNA variants as disease susceptibility alleles. Our results suggest that the 
search may need to include RNA sequence variants that are not in the DNA sequences.  
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Table 2.1 Selected examples of sites that show RNA-DNA Differences in B-cells and EST clones. 
 
Gene Chr Position (bp)* Type 
No. of 
informative 
individuals
†^
 
No. of 
individuals 
with RDD
^
 
Average level
‡^
 
[range] EST 
HSP90AB1 6 44,328,823 A-to-C 11 8 0.39 [0.15, 0.79] BQ355193 (head neck), BX413896 (B 
cell) 
AZIN1 8 103,910,812 A-to-G 17 10 0.22 [0.12, 0.37] CD359333 (testis), BF475970 (prostate) 
CNBP 3 130,372,812 A-to-T 18 16 0.13 [0.10, 0.21] EL955109 (eye), BJ995106 
(hepatoblastoma) 
MYL6 12 54,841,626 C-to-A 16 16 0.35 [0.12, 0.60] EC496428 (prostate), BG030232 (breast 
adenocarcinoma) 
RBM23 14 22,440,217 C-to-G 11 5 0.18 [0.11, 0.35] BQ232763 (testis, embryonic) 
RPL23 17 34,263,515 C-to-T 12 8 0.16 [0.10, 0.22] BP206252 (smooth muscle), CK128791 
(embryonic stem cell) 
BLNK 10 97,957,645 G-to-A 14 7 0.14 [0.11, 0.17] BF972964 (leiomyosarcoma), BE881159 
(lung carcinoma) 
C17orf70 17 77,117,583 G-to-C 2 2 0.26 [0.24, 0.28] AA625546 (melanocyte), AA564879 
(prostate) 
HMGN2 1 26,674,349 G-to-T 7 4 0.22 [0.14, 0.43] BX388386 (neuroblastoma), BE091398 
(breast) 
CANX 5 179,090,533 T-to-A 9 8 0.20 [0.13, 0,30] EL950052, DB558106 
EIF3K 19 43,819,430 T-to-C 19 14 0.16 [0.10, 0.27] AI250201 (ovarian carcinoma), 
AI345393 (lung carcinoma) 
RPL37 5 40,871,072 T-to-G 6 6 0.27 [0.16, 0.45] CF124792 (T cell), DW459229 (liver) 
* hg18 build of the human genome 
^ B-cells 
† RNA-Seq ≥ 10 reads, DNA-Seq ≥ 4 reads 
‡ Calculated by tallying RNA-Seq reads that contain RDD and those that do not.
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Table 2.2 Sanger sequencing of RDD sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* In all cases, matched DNA and RNA samples from the same individuals were sequenced 
† 
Also reported by Li, Levanon et al, 2009(6). 
‡
 Known site that we used as positive control.  ne = not expressed 
Gene Chr 
Position 
(bp)
#
 Type 
Locatio
n 
Amino acid 
change 
B-Cells* Primary Skin Fibroblast* Brain (cortex)* 
# 
informative 
individuals 
# 
individuals 
showing 
RDD 
# 
informative 
individuals 
# 
individuals 
showing 
RDD 
# 
informative 
individuals 
# 
individuals 
showing 
RDD 
EIF2AK2 2 37,181,512 A-to-G 3’ UTR 
Not 
applicable 
8 8 8 0 10 10 
 2 37,181,517 A-to-G 3’ UTR 
Not 
applicable 
8 8 8 3 10 10 
 2 37,181,520 A-to-G 3’ UTR 
Not 
applicable 
8 8 8 3 10 10 
 2 37,181,538 A-to-G 3’ UTR 
Not 
applicable 
8 8 8 6 10 10 
AZIN1
†
 8 103,910,812 A-to-G 
coding, 
exonic 
S to G 2 2 10 0 9 8 
DPP7 9 139,128,755 C-to-T 
coding, 
exonic 
Synonymous 
(P) 
9 2 8 1 10 0 
PPWD1 5 64894960 G-to-A 
coding, 
exonic 
E to K 2 2 8 8 8 8 
HLA-
DQB2 
6 32,833,537 G-to-A 
coding 
exonic 
G to S 2 2 10 10 ne ne 
 6 32,833,545 G-to-A 
coding, 
exonic 
R to H 2 2 10 10 ne ne 
 6 32,833,550 C-to-T 
coding, 
exonic 
Synonymous 
(I) 
2 2 10 10 ne ne 
BLCAP
‡
 20 35,580,977 A-to-G 
coding, 
exonic 
Q to R 6 4 10 4 6 6 
NDUFC2 11 77,468,303 C-to-G 
coding, 
exonic 
L to V 10 0 10 0 10 0 
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Table 2.3 Peptides encoded by both DNA and RNA-forms of mRNA at RDD sites. 
Protein Position (bp)
#
 RDD AA change DNA-form
†
 RNA-form
†
 
AP2A2 chr11:976858 T-to-G Y-to-D YLALESMCTLASSEFSHEAVK DLALESMCTLASSEFSHEAVK 
DFNA5* chr7:24705225 T-to-A L-to-Q VFPLLLCITLNGLCALGR VFPQLLCITLNGLCALGR 
ENO1 chr1:8848125 T-to-C L-to-P EGLELLK EGPELLK 
ENO3 chr17:4800624 T-to-G V-to-G LAQSNGWGVMVSHR LAQSNGWGGMVSHR 
FABP3 chr1:31618424 T-to-A W-to-R MVDAFLGTWK MVDAFLGTR 
FH* chr1:239747217 T-to-A I-to-K IEYDTFGELK KEYDTFGELK 
HMGB1 chr13:29935772 T-to-A Y-to-N MSSYAFFVQTCR MSSNAFFVQTCR 
NACA chr12:55392932 G-to-A D-to-N DIELVMSQANVSR NIELVMSQANVSR 
NSF chr17:42161411 T-to-C V-to-A LLDYVPIGPR LLDYAPIGPR 
POLR2B chr4:57567852 T-to-A L-to-Q IISDGLK IISDGQK 
RAD50* chr5:131979610 T-to-G L-to-R WLQDNLTLR WRQDNLTLR 
RPL12 chr9:129250509 A-to-G N-to-D HSGNITFDEIVNIAR HSGDITFDEIVNIAR 
RPL32* chr3:12852658 G-to-T A-to-S AAQLAIR SAQLAIR 
RPS3AP47* chr4:152243651 C-to-A T-to-K EVQTNDLK EVQKNDLK 
SLC25A17 chr22:39520485 A-to-G E-to-G TTHMVLLEIIK TTHMVLLGIIK 
TUBA1* chr2:219823379 A-to-G E-to-G EDMAALEK EDMAALGK 
TUBB2C chr9:139257297 G-to-A G-to-D LHFFMPGFAPLTSR LHFFMPDFAPLTSR 
 
* DNA sequences of these and others were verified by Sanger sequencing (see Table S2). 
^RDD in RPL28 leads to the loss of a stop codon, the resulting additional peptides are found only in the RNA-form of the mRNA. 
# hg 18 build of the human genome 
† For each peptide, the amino acid that differs between the DNA and RNA forms are underlined. 
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Table 2.4. Corresponding DNA, RNA and peptide sequences at selected sites. 
 
RDD Gene Location DNA*† RNA† 
Peptide 
(DNA-form,LC-MS/MS) 
Peptide 
(RNA-form, LC-MS/MS) 
TtoG CD22 chr19:40514815 CTG CGG ND MHLLGPWLLLR 
TtoA DFNA5 chr7:24705225 CTG CAG VFPLLLCITLNGLCALGR VFPQLLCITLNGLCALGR 
TtoC ENO1 chr1:8848125 CTG CCG EGLELLK EGPELLK 
TtoA FH chr1:239747217 ATA AAA IEYDTFGELK KEYDTFGELK 
TtoA HMGB1 chr13:29935772 TAT AAT MSSYAFFVQTCR MSSNAFFVQTCR 
AtoC HMGB1 chr13:29935469 AAA AAC ND TMSAKEN 
AtoC ITPR3 chr6:33755773 GAC GCC ND DGVEDHSPLMYHISLVALLAACAEGK 
TtoG RAD50 chr5:131979610 CTA CGA WLQDNLTLR WRQDNLTLR 
GtoT ROD1 chr9:114026264 GGA GTA ND NLFIEAVCSVK 
GtoT RPL32 chr3:12852658 GCT TCT AAQLAIR SAQLAIR 
AtoG RPS25P8 chr11:118393375 AAC GAC ND EVPDYK 
CtoA RPS3AP47 chr4:152243651 ACA AAA EVQTNDLK EVQKNDLK 
GtoT SUPT5H chr19:44655806 CAG CAT ND TPMYGSQTPLHDGSR 
TtoC TOR1AIP1 chr1:178144365 TCA CCA ND QPSVLSPGYQK 
AtoG TUBA1 chr2:219823379 GAG GGG EDMAALEK EDMAALGK 
 
 
* DNA sequences are monomorphic according to dbSNP, 1000 Genomes and HapMap Projects; all individuals should have the reference allele. We 
verified this by Sanger sequencing of the B-cells used for mass spectrometry. 
† RDD sites are underlined. 
LC-MS/MS = liquid chromatography and tandem mass spectrometry 
ND = not detected by mass spectrometry; however this does not mean that the peptides are absent in the B-cell proteome. It is likely a result of sampling. 
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Figure 2.1 
 
Fig. 2.1. Characteristics of RDD sites. (A) Frequency of the 12 categories of RNA-DNA differences 
identified in B-cells of 27 normal individuals. (B) Number of RNA editing/ RDD events in 27 normal 
individuals. (C) Bimodal distribution of the levels of 28,766 RNA editing/ RDD events. 
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Figure 2.2 
 
Fig. 2.2. Identification of peptides coded by both RNA and DNA sequences. A) The RNA-form of a RDD 
leads to loss of a stop codon in RPL28 and extension of 55 amino acids. Peptides detected by mass 
spectrometry are shown in red. Extended protein sequence due to RDD is underlined. B & C) MS-MS 
data confirm the detection of peptides encoded by the RDD containing RPL28 mRNA. The representative 
spectra of one peptide (SLIGTASEPR) from ovarian cancer cells (B) and cultured B-cells (C) are shown. 
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Chapter 3: RNA-DNA Differences Are Generated within Seconds After RNA Exits 
Pol II 
Isabel X. Wang1*, Leighton J. Core2*, Hojoong Kwak2,4, Lauren Brady3, Alan Bruzel1,4, Lee 
McDaniel5, Allison L. Richards6, Ming Wu4, Grunseich C7, John T. Lis2†, Vivian G. Cheung1,4, 8† 
The research presented in Chapter 3 has been published as an article: 
Wang IX, Core LJ, Kwak H, Brady L, Bruzel A, McDaniel L, Richards AL, Wu M, Grunseich C, Lis JT, 
Cheung VG. RNA-DNA differences are generated in human cells within seconds after RNA exits 
polymerase II. Cell Rep. 2014 Mar 13;6(5):906-15. doi: 10.1016/j.celrep.2014.01.037. Epub 2014 
Feb 20. 
The work is presented herein with modifications to meet thesis formatting requirements. 
Richards AL contributed to the sequence validation of RDDs and the motif analysis (Table 3.2, 
Figure S3.2B, Figure S3.4) 
Abstract 
RNA sequences are expected to be identical to their corresponding DNA sequences. 
Here, we found all 12 types of RNA-DNA sequence differences (RDDs) in nascent RNA. Our 
results show that RDDs begin to occur in RNA chains about 55 nucleotides from the RNA 
polymerase II (Pol II) active site. These RDDs occur so soon after transcription that they are 
53 
 
 
incompatible with known deaminase-mediated RNA editing mechanisms. Moreover, the 55-
nucleotide delay in appearance indicates they do not arise during RNA synthesis by Pol II or as a 
direct consequence of modified base incorporation. Preliminary data suggest a possible couple 
of RDD formation with R-loops. These findings identify sequence substitution as an early step in 
co-transcriptional RNA processing. 
Introduction 
DNA carries instructions for cellular proteins by providing the code that is transcribed 
into mRNA that in turn is translated into proteins. It is generally assumed that DNA sequences 
are copied faithfully into RNA. However, there are exceptions to this one-to-one relationship 
between RNA and its corresponding DNA sequences. The first example of a transcript sequence 
not encoded by the DNA was reported in 1986 by Benne and colleagues who showed that the 
coxII mRNA in trypanosome has 4 nucleotides not encoded in the DNA. They then coined the 
term RNA editing for this “novel mechanism of gene expression” (Benne et al., 1986). Other 
examples of RNA editing were soon discovered in organisms from plants to metazoans 
(Cattaneo et al., 1989; Driscoll et al., 1989; Gott et al., 1993; Gualberto et al., 1989). In humans, 
RNA editing occurs in processes mediated by ADAR (adenosine deaminases that act on RNA) 
(Bass and Weintraub, 1988) and APOBEC (apolipoprotein B mRNA editing enzymes) (Chen et al., 
1987; Powell et al., 1987) families of proteins which lead to A-to-G (adenosine to inosine which 
is then recognized as guanosine) and C-to-U (cytidine to uridine) changes. Recently, advances in 
sequencing technologies have enabled deep sequencing of DNA and RNA which allowed us (Li 
et al., 2011) and others (Alon et al., 2012; Bar-Yaacov et al., 2013; Chen, 2013; Chen et al., 
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2012; Ju et al., 2011; Lagarrigue et al., 2013; Peng et al., 2012; Silberberg et al., 2012; Vesely et 
al., 2012) to uncover more RNA-DNA sequence differences (RDDs) than canonical RNA editing 
events. In different human cells and by using various sequencing and analytical methods, we 
and others have found all 12 types of RDDs. 
 While the mechanisms that mediate A-to-G and C-to-U editing in humans are known, we 
do not know how the other types of RDDs arise. For instance, A-to-C transversions are not likely 
to be mediated by ADAR and APOBEC families of deaminases. In this project, we ask when RDDs 
arise in order to distinguish the different types of underlying mechanisms. To address this, we 
compared nascent RNA sequences with their corresponding DNA sequences. The results show 
that all 12 types of RDDs occurred early during transcription. We found RDDs in transcripts 
beginning at approximately 55 bases from the active site or approximately 35 bases beyond the 
exit channel of RNA polymerase II (Pol II). This demonstrates that the RDD events occur by a 
mechanism distinct from altered base selectivity during catalysis of chain elongation by Pol II; 
nonetheless, the RNA processing events that mediate RDDs are closely coupled temporally and 
spatially to transcription in human cells. Given that RDDs emerge so soon after transcription, 
we studied cells from a patient with autosomal dominant form of juvenile ALS due to mutation 
in senataxin gene and found suggestive evidence that RDD formation may be coupled to R-
loops.  
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Nascent RNA from GRO-seq and PRO-seq 
To determine whether RDDs occur during or after transcription, we sequenced nascent RNA 
using two global run-on sequencing methods, GRO-seq (Core et al., 2008) and precision run-on 
sequencing, PRO-seq (Figure 3.1A) (Kwak et al., 2013). We obtained ~ 100 million 100-
nucleotide uniquely mapped GRO-seq reads from B-cells of two individuals. For one subject, we 
carried out two independent PRO-seq experiments and obtained ~60 million uniquely mapped 
reads in each. Additionally, we isolated and sequenced nascent RNA with an alternate method 
(Wuarin and Schibler, 1994) for comparison (chromatin-bound RNA-seq) (~190 million uniquely 
mapped reads). Finally, we carried out mRNA sequencing (mRNA-seq) and obtained ~135 
million uniquely mapped RNA-seq reads, and sequenced the corresponding genomic DNA of the 
two individuals to 30X and 60X coverage. 
We began by assessing the distributions of mapped reads from the libraries obtained by 
these four independent methods. As expected (Core et al., 2008; Kwak et al., 2013), GRO-seq 
and PRO-seq enriched for sequences near transcription start sites (Figure 3.1B, TSS). This 
enrichment in mammalian cells is due to promoter proximal pausing (sense strand) and 
upstream divergent transcription (antisense strand) (Core et al., 2008; Seila et al., 2008). 
Additionally, GRO-seq and PRO-seq data provide sensitive detection of active transcription units 
and identify over 9,000 transcriptionally-active genes. To ensure that we are looking at very 
nascent RNAs, we assessed the extent of splicing in GRO-seq and PRO-seq relative to 
chromatin-bound nascent RNA and mRNA. While about 20% of the mRNA-seq reads and 5% of 
the chromatin-bound nascent transcripts cover exon-exon junctions, less than 1% of the GRO-
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seq and PRO-seq reads span junctions. These nascent transcripts map throughout transcription 
units including introns (Core and Lis, 2008; Core et al., 2008; Core et al., 2012), while mRNA-seq 
libraries are dramatically depleted of introns but enriched in the 3’ untranslated regions due to 
sample preparation for polyadenylated transcripts. These findings support that GRO-seq and 
PRO-seq correspond to greatly enriched short nascent RNA that is newly synthesized (also 
referred to as “very nascent RNAs” below), while chromatin-bound RNA represents longer 
transcripts on average from a later stage (referred to as “nascent RNA”). Figure 3.1C shows 
representative results for UVRAG and CAPZB from sequencing nascent and mature RNAs. 
We also compared the expression levels of genes in the very nascent and mature 
mRNAs. The very nascent RNA differs from mature RNA in that the very nascent RNA levels 
depend on density of transcribing Pol II, while the mRNA levels depend on the rate of both 
transcription and mRNA decay. However, levels of transcripts in the two are significantly 
correlated (r=0.45, P<<0.0001) (Figure 3.1D) with outliers representing very stable or unstable 
mRNAs. 
RDDs in very nascent RNA 
Next, we turned to study RDDs in nascent RNA. Defining when RDDs arise during 
nascent transcription should help rule out or support particular mechanisms by which they are 
generated. Therefore, we analyzed the RNA sequences and their corresponding DNA sequences 
to assess how early during transcription the RNA-DNA differences arise. The steps to identify 
RDDs are shown in Figure 3.2. At sites that are covered by at least 10 uniquely mapped GRO-
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seq or PRO-seq reads and 10 monomorphic DNA reads (that contain only one nucleotide type: 
A, C, G or T), we compared the nascent RNA and corresponding DNA sequences and identified 
sites where RNA and DNA sequences are discordant. For a site to be identified as a candidate 
RDD, at least 10% of the GRO-seq or PRO-seq reads at that site (and a minimum of 2 unique 
reads) has to contain a sequence that differs from the underlying DNA sequences. All the 
resulting potential RDD sites were further processed in multiple steps to confirm their unique 
genomic locations. Several additional experiments and analyses were carried out and they 
confirmed that the RDDs are not due to sequencing errors or mistakes introduced by reverse 
transcription (see supplemental experimental procedures for details). 
The results uncovered 2,806 RDDs in one subject (GM12004), and 2,881 RDDs in the 
other individual (GM12750) (Tables S3.1 & S3.2). The orientation-specific sequencing allows us 
to distinguish all 12 possible types of mismatches between DNA and corresponding RNA 
sequences. In this analysis, we excluded C-to-T RDDs because the use of 5-bromouridine 5’-
triphosphate (BrUTP) in GRO-seq may favor this type of misincorporation (Yu et al., 1993). All 
the 11 remaining types of RDDs were found; C-to-G was the most common in both samples 
(Figure 3.3A). We analyzed the PRO-seq data in the same way. Except for the 3’ most 
nucleotide, the sequenced RNAs from the PRO-seq sample are made in the cell (as opposed to 
about half in GRO-seq) thus it gives us longer segments of in vivo synthesized RNAs for analysis. 
We found 23,093 RDD sites out of about 115 million nucleotides screened, corresponding to 
one to two RDD per 10,000 bases screened and a frequency of ~ 2 X 10-4 RDD in the PRO-seq 
sample (Table S3.3) which is comparable to the frequency of RDD in mRNAs (also 10-4) (Li et al., 
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2011). All 12 types of RDDs were identified (Figure 3.3B). Even though both GRO-seq and PRO-
seq are global run-on assays coupled with deep sequencing, they are not identical, therefore 
different numbers of RDDs were detected in the two assays. Unlike GRO-seq, PRO-seq does not 
use BrUTP; thus miscorporation that favors C-to-T discordance is not a concern; therefore, we 
included all 12 types of RDDs in our analysis. This added more than 1,700 RDD sites (1,793 C-to-
T). In addition, nearly the entire (except one or at most a few bases) PRO-seq transcripts as 
compared to ~15 to 20% of the GRO-seq transcripts are made in vivo. Together the addition of 
the C-to-T sites and the longer in vivo synthesized transcripts, allowed us to identify about 8X 
more RDD sites in PRO-seq than GRO-seq. Despite the differences in the number, the 
distributions of RDD types are similar between GRO-seq and PRO-seq samples and across 
different thresholds of coverage and RDD levels (Figure S3.1). This reflects the robustness of our 
analysis. 
 Next, we examined RDDs from different experiments for overlaps. As one expects, the 
overlaps of RDD sites between the run-on experiments are low, since the ability to resample an 
RDD site in independent run-on assays depends on several parameters, including the density of 
transcribing Pol II, sequence depth, and RDD levels. GRO-seq and PRO-seq identify RDD sites in 
nascent RNA sequences that are closely associated (<100 nucleotides) with actively transcribing 
polymerases. Finding the same RDD event in two independent samples relies on sampling an 
RDD-bearing transcript bound to actively transcribing polymerases in both experiments; the 
chance of such occurrence is very low. The RDD identification also depends on sequence depths 
and the RDD levels (= number of RDD-containing reads/ total number of reads at the site). The 
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median RDD level among the sites detected in GRO-seq and PRO-seq is 0.24, therefore high 
coverage (~40x) is needed to obtain 80% of them in replicate samples (Chen, 2013). 
Nonetheless, 108 RDD sites were found in more than one sample (among the two GRO-seq and 
one PRO-seq datasets). The RDD sites we found in nascent RNAs were also present at a later 
stage of transcription. In chromatin-bound transcripts where we have longer transcripts and 
deeper coverage, we found over 1,000 RDD sites from one of the GRO-seq and/ or PRO-seq 
libraries. The distributions of these RDD sites are similar to those in GRO-seq and PRO-seq: T-to-
G is one of the more abundant types and A-to-T is less frequent. These results show that the 
RDDs in nascent RNAs can be identified by different assays.  
RDD formation occurs within seconds after transcription 
To address how early during transcription do RDD events emerge, we first examined the 
GRO-seq results. As shown in Figure 3.1A, the GRO-seq reads comprise very nascent RNAs 
transcribed in vivo before nuclei isolation and a portion transcribed in vitro during the run-on. 
Since our very nascent RNAs are triple selected for BrU incorporation and we selectively 
analyzed reads with an identifiable 3’-end of the nascent RNA, the 3’-portion must contain the 
in vitro transcribed RNA and the 5’-portion contains some in vivo synthesized RNA. For both B 
cell samples, the majority of the RDDs are found in the 5’ portion of the GRO-seq samples, 
which is enriched for the in vivo made nascent RNA (Figure 3.4A). These represent newly 
synthesized transcripts that have just exited the actively transcribing polymerase. These 
findings suggest that RDDs result from transcription-coupled RNA processing steps. 
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 To further refine the time frame for these RDD events, we used PRO-seq to localize 
more precisely the RDD sites relative to actively transcribing RNA Pol II. In PRO-seq, the in vitro 
run-on assay was allowed only to proceed for one or at most a few nucleotides, thus the 3’ 
ends of the PRO-seq reads mark precisely the locations of the transcriptionally active RNA 
polymerases in our B-cells. This offers an opportunity to examine nascent RNAs that have just 
exited the active site of Pol II. We examined where the RDDs were found relative to the actively 
transcribing Pol II, and as seen in the GRO-seq data, the RDD events occur after the RNA has 
exited the polymerase (Figure 3.4B). Moreover, the increased precision and accuracy afforded 
by PRO-seq allowed us to observe the abrupt increase at ~55 nucleotides from the active site of 
Pol II, corresponding to the sharp increase in RDD events around position 40 of the PRO-seq 
reads. As depicted in Figure 3.4B, the first ~20 bases from the 3’ ends of the reads are nascent 
RNAs covered by RNA polymerase II, thus, RDD sites begin to appear about 35 bases after the 
RNA exits the polymerase. To confirm this observation, we repeated a PRO-seq experiment. The 
results confirmed our finding of an increase in RDD at ~55 nucleotides from the active site of 
Pol II (Figure S3.3A). In contrast, the RDDs found in mature mRNAs are more uniformly 
distributed as expected (Figure 3.4C). These results are consistent with those from GRO-seq and 
demonstrate that RDD events appear to occur very rapidly (within seconds) after the nascent 
RNA is exposed, and are not occurring in the Pol II active site during the catalytic step of 
synthesizing RNA. 
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RDD frequency is lower in cells from a patient with Senataxin mutation 
Our findings that RDDs emerge soon after nascent transcripts exit from transcription 
bubbles suggest the coupling of RDDs with R-loops (White and Hogness, 1977) which also 
initiate behind RNA polymerase. We therefore examined and found that RDDs are enriched 
significantly (P<0.001) in regions with R-loop forming sequences (Figure 3.4D & S3.3B) (Ginno et 
al., 2012; Wongsurawat et al., 2012). To study the co-occurrence of RDDs and R-loops, we 
carried out PRO-seq using cells from a patient with autosomal dominant form of juvenile 
Amyotrophic Lateral Sclerosis (ALS4) due to a mutation (L389S) in the Senataxin (SETX) gene 
that encodes a DNA/RNA helicase (Chen et al., 2004). The senataxin protein, SETX, interacts 
with RNA polymerase II (Chen et al., 2006; Ursic et al., 2004; Yuce and West, 2013) and plays a 
role in resolving R-loops particularly in transcription pause sites (Mischo et al., 2011; Skourti-
Stathaki et al., 2011; Suraweera et al., 2009; Yuce and West, 2013). The mutation at position 
389 corresponds to the N-terminus of SETX that interacts with other nuclear proteins including 
RNA polymerase II (Yuce and West, 2013). We found that there are 50% fewer RDDs in the very 
nascent RNA of the ALS4 sample; a frequency of 9 x 10-5 compared to 2 x 10-4. Compared to 
controls, the RDD sites in the ALS4 sample skewed away from G-bearing transcripts; there are 
significantly more (P=0.03 (t-test)) RDD events that convert G in the DNA to other bases in the 
RNA (32% vs. 12% G-to-X, where X = A, C, or T (U)). Since R-loops preferentially form around 
nascent RNA that is G-rich (Roy and Lieber, 2009), this observation suggests the fewer RDDs in 
the ALS4 sample may be due to less efficient resolution of R-loops. These results encourage 
further studies to uncover the mechanistic connection of R-loops and RDDs. 
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A-to-G RDDs in very nascent RNA are not mediated by ADAR 
 In our B-cells, the only known editing mechanism is ADAR-mediated A-to-G editing 
(APOBEC1 is not expressed), so we asked if the A-to-G discrepancies in the nascent RNAs can be 
explained by ADAR proteins. Previously, ADAR-mediated editing was found in nascent RNA of 
Drosophila (Rodriguez et al., 2012) where nascent RNA was defined as chromatin-bound 
transcripts. We examined our chromatin-bound transcripts and mature poly-adenylated RNA, 
and found A-to-G editing events in both fractions, consistent with results in Drosophila. 
However, we did not find these A-to-G sites in GRO-seq or PRO-seq. For example, from mRNA-
seq, we identified 65 A-to-G sites in POLH, and 48 of the adenosines were also edited in 
chromatin-bound RNA; but, none of these A-to-G sites were detected in the nascent RNA from 
GRO-seq or PRO-seq despite good sequence coverage (Figure S3.3C). For a more 
comprehensive analysis, we turned to results from several recent studies that have identified 
over 10,000 A>G editing sites (Bahn et al., 2011; Carmi et al., 2011; Kiran and Baranov, 2010; Li 
et al., 2009; Peng et al., 2012). None of the RDD sites in GRO-seq overlap with the editing sites 
reported in those studies. However, there are some A-to-G events in nascent RNA from GRO-
seq and PRO-seq, so we compared the features of these A-to-G sites in nascent RNA with those 
known to be edited by ADAR-mediated deamination. We found that the sequence 
characteristics of the A-to-G sites in nascent and mature RNAs appear to be different. Most 
(>95%) of the ADAR-mediated A-to-G sites in polyadenylated mRNAs are found in Alu repeats 
(Athanasiadis et al., 2004; Chen, 2013), but in contrast, the A-to-G sites in very nascent (GRO- or 
PRO-seq) RNAs are not in Alu containing regions. In addition, the A-to-G sites in very nascent 
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RNAs do not have the sequence motif (5’ depletion of G (Lehmann and Bass, 2000)) that flanks 
ADAR-edited adenosines (see Fig S4A) (Wang et al., 2013). The data suggest that there are two 
distinct classes of A-to-G mismatches; those that are mediated by ADAR, and others that use a 
separate mechanism occurring on very nascent RNA during transcription.  
Other characteristics of RDDs in very nascent RNA 
Previous studies of RDDs focused on polyadenylated mRNAs (Bahn et al., 2011; Ju et al., 
2011; Li et al., 2011; Peng et al., 2012); the very nascent RNAs in the present study allowed us 
to assess RDDs in regions such as introns that were spliced out in mature transcripts. Many of 
the RDDs in very nascent RNAs are found in intronic regions (28%), which could potentially 
affect downstream RNA processing steps. In addition, nearly half (44%) of the RDDs are 
intergenic (many of these correspond to gene isoforms with longer 5’ and 3’ UTRs relative to 
the REFseq forms). The remaining (28%) are found in exonic regions and evenly divided among 
coding exons and UTRs (48% and 52%, respectively). As we found previously (Li et al, 2011), 
unlike SNPs, there is no bias against nonsynonymous changes as ~70% of the coding RDD sites 
lead to alternate amino acids as predicted by the codon table. We studied the genes that 
contain RDD sites in nascent RNA and found that they are significantly (P<10-30) enriched for 
roles in regulation and metabolism of nucleic acids and other macromolecules (see Table 3.3).  
 We also examined the sequences (10 bases) surrounding the RDD sites and showed that 
sequence context may be important. RDDs with the same DNA base share similar sequence 
characteristics. In particular, C-to-A and C-to-G, and the G-to-A, G-to-C and G-to-T RDDs share 
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similar surrounding sequences. The RDDs whose DNA base is C reside in regions that are 
significantly more C-rich, while RDDs whose DNA base is G reside in regions that are 
significantly more G-rich than negative controls (Figure S3.4B & C) (t-test, P< 0.05). The 
enrichments of these nucleotides extend in both the 5’ and 3’ directions. These regions are 
more C-rich and G-rich, but they are not homopolymer tracts of Cs or Gs (Figure S3.4D). Thus, 
these are different from the co-transcriptional editing of homopolymer tracts in Ebola 
(Volchkov et al., 1995) and paramyxoviruses (Cattaneo et al., 1989; Paterson and Lamb, 1990). 
Additionally, RDDs whose DNA base is C show depletion of G at the base 3’ of the RDD, and 
those whose reference base is G show depletion of C at the base 5’ of the RDD. These features 
may affect the DNA and/or RNA structures, or possibly an RNA/DNA hybrid, which in turn 
signals for an RDD event as mentioned above. 
Conclusions 
 We presented data from studying where RDDs occur and put them in context of known 
RNA editing mechanisms. We showed all 12 types of RDDs are found in RNAs that have recently 
extruded from the RNA Pol II exit channel. The RDD events occurred in vivo on transcripts about 
35 nucleotides from the exit channel of Pol II. Pol II elongates in mammalian cells at 20 to 60 
bases per second (Ardehali and Lis, 2009). Therefore, the RDD events found ~35 bases from the 
exit channel must occur very shortly after nascent RNA synthesis. Thus, our results indicate that 
RDDs are likely to occur within a few seconds of RNA synthesis and before classic RNA editing 
events. RNAs synthesized by RNA polymerase II are quickly modified: 5’ caps are added as the 
RNA end exits the Pol II RNA channel (Rasmussen and Lis, 1993), introns are often spliced co-
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transcriptionally (Carrillo Oesterreich et al., 2010; Vargas et al., 2011) and 3’-ends are cleaved 
and polyadenylated before Pol II terminates transcription (Osheim et al., 2002). Based on 
knowledge of co-transcriptional processing events and results from the present study, we 
suggest that RDD occurs soon after the capping of the transcripts and before splicing. 
The reason that we looked for timing of RDD is to help us to narrow the search for the 
underlying mechanisms that mediate its formation. A co-transcriptional event that coincides 
temporally with RDD formation is the emergence of R-loop (Broccoli et al., 2000; Drolet et al., 
1995; Masse and Drolet, 1999). As a preliminary examination of whether there is association 
between RDD and R-loop, we studied RDDs in very nascent RNA of cells from a juvenile ALS 
patient with a mutation in the senataxin gene(Chen et al., 2004). The RNA/DNA helicase, 
senataxin, interacts with RNA polymerase and mediates the resolution of R-loops. We found 
that the patient has about 50% fewer RDDs in her nascent RNAs. The RDDs seem to be 
associated with R-loop since there is enrichment in R-loop forming sequences (Ginno et al., 
2012) around RDD sites and depletion of G-bearing RDD transcripts in patient. These findings 
points to possible coupling of RDD and R-loop formations, and encourage further studies to 
uncover the molecular basis. 
GRO-seq and PRO-seq assays allowed us to study very nascent RNA for RDD formation. 
But these methods also limit us to study sequences that are covered by or immediately 
adjacent (<100 bases) to actively transcribing polymerases. It is possible that there are other 
mechanisms, like ADAR-mediated editing, that modify RNA transcripts at a later stage of RNA 
processing. While our results show that RDD formation occurs very soon after RNA synthesis, 
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they do not imply that all RDD formations have to occur as early co-transcriptional steps. 
Additional methods may be needed to identify or rule out existence of other processing steps 
that modify RNA sequences. Comparison of RNA sequences at different stages of maturity 
alone will not provide a comprehensive view because the levels of many RDD sites are low 
(below 30%), therefore the depth of sequencing necessary to conclude that a RDD site is absent 
in one stage of transcript synthesis but present in subsequent stages is difficult to achieve with 
current sequencing technologies given the constraints of error rate and cost. However, 
technologies to isolate RNA from different subcellular compartments and advances in sequence 
analysis are improving quickly; they soon will allow the tracking of individual transcripts 
through various processing steps and thus facilitate the determination of whether there are 
additional events that modify RNA sequences.  
In summary, we have identified sequence modification as an early RNA-processing step 
thus adding to the already complex set of events that add diversity to transcriptomes. 
Experimental Procedures 
DNA sequencing. Cultured B-cells from two normal individuals in the Centre d’Étude du 
Polymorphisme Humain database, GM12004 and GM12750, were obtained from Coriell Cell 
Repositories (NJ, USA). DNA-seq libraries were prepared and sequenced on HiSeq instrument to 
obtain 60X and 30X coverage, respectively (Illumina).  
mRNA-seq and chromatin-bound nascent RNA-seq. For mRNA sequencing, RNA-seq libraries 
were prepared following Illumina TruSeq RNA sample preparation protocol. Chromatin-bound 
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nascent RNA was extracted as previously described (Wuarin and Schibler, 1994). The mRNA and 
chromatin RNA were sequenced on HiSeq instrument. 
GRO-seq and PRO-seq. Nuclei were isolated from cultured B cells and GRO-seq libraries were 
prepared with 5X106 nuclei as described previously (Core et al., 2008, 2012). PRO-seq libraries 
were prepared as described previously (Kwak et al., 2013). Briefly, 5×106 nuclei were added to 2 
X Nuclear Run-On (NRO) reaction mixture (10 mM Tris-HCl pH 8.0, 300 mM KCl, 1% Sarkosyl, 5 
mM MgCl2, 1 mM DTT, 0.375 mM each of biotin-11-A/C/G/UTP (Perkin-Elmer), 0.8 u/µl RNase 
inhibitor) and incubated for 3 min at 30˚C. Nascent RNA was extracted and fragmented by base 
hydrolysis in 0.2 N NaOH on ice for 10~12 min, and neutralized by adding 1 X volume of 1 M 
Tris-HCl pH 6.8. Fragmented nascent RNA was purified using streptavidin beads, ligated with 
reverse 3’ RNA adapter (5'p-GAUCGUCGGACUG-UAGAACUCUGAAC-/3’InvdT/), and biotin-
labeled products were enriched by another round of streptavidin bead binding and extraction. 
For 5’ end repair, the RNA products were successively treated with tobacco acid 
pyrophosphatase (TAP, Epicentre) and polynucleotide kinase (PNK, NEB). 5’ repaired RNA was 
ligated to reverse 5’ RNA adaptor (5'-CUGAACAAGCAGAAGACGGCAUACGA-3') before being 
further purified by the third round of streptavidin bead binding and extraction. RNA was 
reverse transcribed using 25 pmol RT primer 
(5’AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA-3’). The product was amplified 
15±3 cycles and products greater than 150 bp (insert > 70 bp) were PAGE purified before being 
analyzed by Illumina HiSeq 2500 instrument. Two PRO-seq experiment was carried out, one at 
68 
 
 
the Lis lab at Cornell University (Figure 3.3&3.4), and one at the Cheung lab at University of 
Pennsylvania (Figure S3.3A).  
Sequence analysis. DNA-seq and RNA-seq reads were aligned to human reference genome 
(hg18) using GSNAP (Wu and Nacu, 2010) (version 2012-04-10). A list of SNP sites in the CEU 
population from Hapmap (release #28) and 1000 Genomes (pilot project) was used for SNP-
tolerant alignments. Alignments with (read length + 2)/12 – 2 or fewer mismatches were 
obtained for each read. PRO-seq sequences were converted to the reverse-complements 
before alignment. For RNA sequence analysis, known exon-exon junctions (defined by RefSeq 
(downloaded March 7, 2011) and Gencode (version 3c)) and novel junctions (defined by 
GSNAP) were accepted. Read coverage was analyzed using RSeQC and RPKM (read per kilobase 
per million reads) for each gene were calculated (Wang et al., 2012). For GRO-seq and PRO-seq, 
we include all the reads covering exon or intron region in computing RPKM, while excluding 
1kb-region downstream of TSS which is overrepresented by short transcripts associated with 
proximally paused Pol II. 
RNA-DNA differences. To identify RDDs, we compared RNA sequence to its corresponding DNA 
sequence. Low-quality bases (Phred quality score < 20) in both the RNA and DNA were 
removed. To be included as RDD sites in the final lists, the following criteria had to be met: 1) a 
minimum of 10 total DNA-seq reads covering that site; 2) DNA sequence at this site is 100% 
concordant, without any DNA-seq reads containing alternative alleles; 3) a minimum of 10 total 
RNA-seq reads covering that site; 4) level of RDD (# of RNA-seq reads containing non-DNA 
allele/# all RNA-seq reads covering a given site) is ≥10% (a minimum of two RNA-seq reads 
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containing RDD). To ensure the accuracy of the RDD sites, additional filtering steps were 
performed using two additional mapping algorithms. See supplemental experimental 
procedures for further details. 
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Table 3.1. Results of genome-walking confirm that RDDs are in unique regions of the genome. 
 
Genomic location RDD type 
Plus strand Minus strand 
Sequence # clones Sequence # clones 
chr1:152175284 G-to-A G 31 G 9 
chr6: 107088915 T-to-A T 19 T 21 
chr9:34336911 G-to-A G 14 G 10 
chr11:72079055 T-to-C T 10 T 10 
chr12:100980077 A-to-C A 11 A 18 
chr14:20221257 G-to-T G 14 G 16 
chr16: 2140620 A-to-G A 2 A 14 
chr19: 2427122 C-to-A C 15 C 1 
chr22:42867269 T-to-C T 13 T 14 
chrX:7004437 G-to-T G 11 G 10 
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Table 3.2. ddPCR validation of GRO-seq RDDs. 
Genomic 
Location 
Gene Name 
RDD 
Type 
Feature Individual 
Level in nascent RNA 
GRO-seq (%)
ᵻ
 ddPCR (%) 
1:152175284 DENND4B* G>A 
Coding 
exon 
GM12004 20 15 
GM12750 0 0 
3:197100758 TNK2 G>T Intron 
GM12004 0 0 
GM12750 9 9 
6:161450890 MAP3K4* G>T 
Coding 
exon 
GM12004 17 1 
GM12750 0 2 
6:37987903 ZFAND3 G>C Intron 
GM12004 0 0 
GM12750 7 3 
9:34336911 ---- G>A Intergenic 
GM12004 8 19 
GM12750 14 27 
11:58103493 ZFP91 G>C 
Coding 
exon 
GM12004 0 0 
GM12750 18 10 
11:72079055 ARAP1* T>C Intron 
GM12004 0 0 
GM12750 11 7 
12:100980077 ---- A>C Intergenic 
GM12004 18 17 
GM12750 0 0 
16:69880869 FTSJD1 C>G 5’ UTR 
GM12004 9 3 
GM12750 0 0 
17:30949447 AP2B1 G>C Coding exon 
GM12004 0 0 
GM12750 10 16 
18:8628755 RAB12* T>C 3’ UTR 
GM12004 0 0 
GM12750 11 9 
17:34815068 MED1 G>T 3’ UTR 
GM12004 0 0 
GM12750 13 10 
19:2197783 SF3A2 G>C 
Coding 
exon 
GM12004 0 0 
GM12750 33 10 
X:7004437 HDHD1A* G>T Intron 
GM12004 43 50 
GM12750 0 0 
 
* Also found in nuclear RNA fractions of both individuals (Figure S4) except the site in HDHD1A was found in GM12004 but not 
GM12750. 
ᵻ
 We included a few RDD sites with levels <10% in the validations even though the analyses focused on sites whose levels are 
>10%. As shown, even the sites with lower levels were validated by ddPCR analysis of these same libraries.  
  
 77 
 
Table 3.3. Genes with RDDs in their nascent RNAs are enriched for roles in regulation and 
metabolism of macromolecules. 
GO Term Examples P-value 
gene expression RNF10, ZNF791, KDM2B; DHX9; ELF4 1.8 X 10
-60
 
nucleic acid metabolic process SP3, MAX, RPS6KA4; PSMD11; UTP23 6.2 X 10
-60
 
RNA metabolic process RPS24; ELF1; CPEB2; DHX9; NFX1 2.6 X 10
-58
 
cellular macromolecule biosynthetic process DPF1; SEC14L2; RPL18A; UPF1; HARS 4.5 X 10
-53
 
macromolecule biosynthetic process ARFRP1;CTBP2; TSG101; GTF3C2; PARP10 4.3 X 10
-51
 
regulation of macromolecule metabolic 
process 
AXIN1; FYN; VCP; SMARCA5; ZNF7 3.9 X 10
-50
 
regulation of cellular metabolic process BCOR; ELL; MTF1; STAT5A; VPS36 2.4 X 10
-49
 
cellular protein metabolic process CCT8; TCF3; RNF115; UBE4B; LNX1 4.9 X 10
-49
 
regulation of primary metabolic process ATG7; CLIP3; YLPM1; CD44; POGK 8.6 X 10
-47
 
regulation of nitrogen compound metabolic 
process 
AGRN; SMARCC1; MOV10; SUMO1; HSPA8 4.6 X 10
-36
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Figure 3.1 
 
Figure 3.1. GRO-seq and PRO-seq analysis. (A) Schematic of GRO-seq and PROseq. (B) Comparison 
between GRO-seq and PRO-seq. Sense and antisense transcripts associated with transcription start sites 
(TSS) are shown for GRO-seq and PRO-seq samples. The slight shift of the PRO-seq promoter-proximal 
peak downstream relative to the GRO-seq peak is because the PRO-seq reads that were less than 35 
nucleotides were not mapped in the analysis, and because GRO-seq maps 5’ ends and PRO-seq maps 3’ 
ends of nascent RNAs. (C) mRNA-seq, chromatin-bound nascent RNA-seq, GRO-seq and PRO-seq results 
for two representative genes, UVRAG and CAPZB. For genes with proximal Pol II pausing such as UVRAG, 
there are more reads mapping to the 5’ ends of genes in both GRO-seq and PRO-seq samples. Schematic 
gene structure is aligned to mRNA-seq results, with boxes representing exons, lines representing introns 
and arrowheads showing direction of transcription. Coverage is calculated using bin size of ~ 1500 bp 
and 600 bp, respectively. (D) Scatter plot of gene expression levels from GRO-seq and mRNA-seq 
(FPKM>0.1). Results from GM12750 (shown) and GM12004 are similar (r=0.45 for both samples). 
Heatmap indicates frequency of different expression levels. 
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Figure 3.2 
 
Figure 3.2. Analysis steps to identify RNA-DNA sequence differences. See also Table S1-S3. 
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Figure 3.3 
 
Figure 3.3. RNA-DNA differences in very nascent transcripts. Distributions of RDD types (A) in GRO-seq 
samples of two individuals, (B) in PRO-seq. RDD types were ordered as in (A) and C-to-T RDDs for the 
PRO-seq sample. 
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Figure 3.4 
 
Figure 3.4. Locations of RDD sites within sequencing reads. (A) Locations of RDD sites along 
GRO-seq reads. Only reads that have defined 3’ ends (reads that contain 3’ adapter sequences) 
were included in our analysis. (B) Locations of RDD sites along PRO-seq reads. Schematic 
diagrams indicate the locations of the different segments of GRO-seq (A) and PRO-seq (B) 
transcripts along the sequence reads. (C) Locations of RDD sites along mRNA-seq reads. (D) R-
loop forming sequences are enriched in regions immediately adjacent to RDD sites. Average R-
loop scores for 2 kb of regions up and downstream of RDD sites are shown. RDDs on positive 
and negative strands are calculated separately. RDD sites have significantly higher R-loop scores 
(P<0.001, t-test) than random control sites shown in Figure S3B. 
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Chapter 4: Cis Regulation of RNA Editing in Human 
 
Abstract 
RNA sequences are expected to be identical to the corresponding DNA sequences. 
Recent studies have found that the RNA sequences do not match their DNA templates at 
thousands of sites throughout the human transcriptome. Many of these mismatches can be 
attributed to RNA editing mediated by Adenosine Deaminase Acting on RNA (ADAR). ADAR 
enzymes deaminate adenosine to inosine which is then read by translational machinery as 
guanosine. In our analysis, we focus on 8,837 A-to-G editing sites found in B-cells of ten 
individuals. We found that RNA editing levels vary among individuals. We searched for cis 
variation near these editing sites and found evidence of allelic association with editing levels. 
We further studied an editing site found in the 3’ untranslated region of SEC16A, a gene 
involved in protein transport. Our data suggest that editing of SEC16A may influence the 
binding of proteins involved in RNA transcript stability. This work sheds light on the regulation 
of editing and the effect of editing on RNA processing. 
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Introduction 
 Recent studies have shown that RNA editing and other types of RNA-DNA sequence 
Differences (RDDs) are widespread throughout the human transcriptome (Li et al., 2011, 
Ulbricht and Emeson 2014). An abundant type of RNA editing in humans is mediated by 
Adenosine Deaminase Acting on RNA (ADAR). ADAR enzymes deaminate adenosine to inosine, 
which is read as guanosine by the protein translation and RNA splicing machineries (Savva et al., 
2012). ADAR recognizes double-stranded RNA structures. This preference causes many ADAR 
editing sites to occur in Alu elements as multiple Alu insertions in a given transcript can lead to 
a long double-stranded RNA structure (Athanasiadis et al., 2004, Levanon et al., 2004).  
The majority of Alu elements, and in turn editing sites, occur in non-coding regions. 
Specifically, about 90% of ADAR editing sites are found in non-coding regions, such as intronic 
or untranslated regions (Wang et al., 2013). Studies have demonstrated that RNA editing in 
non-coding regions can affect RNA processing, such as splicing (Athanasiadis et al., 2004, Lev-
Maor et al., 2007) and transport (Zhang and Carmichael 2001).  
ADAR edits thousands of sites in the human transcriptome and little is understood about 
the regulation of editing. Previous studies have demonstrated that ADAR preferentially edits 
adenosines without a guanosine at the upstream base but with a guanosine at the downstream 
base (Polson and Bass 1994, Lehmann and Bass 2000, Eggington et al., 2011). While these 
preferences have been well-established, it is still unclear how sequences located further from 
the target site may affect the efficiency of ADAR editing. ADAR editing levels vary not only 
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across sites but also across individuals (Li et al., 2011). This caused us to ask whether the 
variability in editing levels may be affected by genomic variations acting in cis. 
In this work, we leveraged individual variation to study the heritability and regulation of 
RNA editing. We find allelic association of RNA editing with nearby DNA sequence 
polymorphisms thus suggesting that RNA editing level is genetically regulated. Further, we 
characterize an editing site in the 3’UTR of SEC16A, a gene whose protein product is involved in 
vesicle transport from the endoplasmic reticulum to the Golgi apparatus (Watson et al., 2006). 
Our data suggest that editing of this site in SEC16A may influence RNA transcript stability 
through affecting an RNA binding protein. Together, this study demonstrates that RNA editing 
levels can be heritable and may contribute to individual differences in cellular processes, such 
as RNA decay. 
Identification of RNA editing and RDDs in Human B-cells 
In order to identify ADAR A-to-G RNA editing sites and other single-base differences, we 
utilized RNA-sequencing data from ten B-cell lines derived from unrelated individuals (Figure 
S4.1). The RNA sequencing data were compared to the reference genome (hg18) to identify 
positions where the RNA did not match the corresponding DNA sequence. We did not consider 
sites that were found to be SNPs by dbSNP (build 138), 1000 genomes, or the Exome 
Sequencing Project. We removed repetitive elements (except for Alu elements due to their high 
probability of containing ADAR editing sites) and pseudogenes. To call an RNA editing site or 
RNA-DNA sequence Difference (RDD), we required that there are at least 10 total reads at the 
position and that 5% of the reads contain the alternative base. If this requirement was met in at 
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least two of the ten individuals, the site was included in the analysis. We define an RDD to be 
any single-base difference that cannot be explained by canonical editing in our cells. This means 
that an RDD in this dataset is any difference except A-to-G. The known cytidine deaminases, 
APOBEC1 and A1CF, are not expressed in our cells (fragments per kilobase of exon per million 
fragments mapped (FPKM) ~0 for both genes across B-cells from 10 individuals) so we include 
C-to-U in our RDD list. 
These sites were further queried against the 1000 genome database of 99 CEU 
individuals and by DNA-sequencing of 4 of our 10 individuals to ensure homozygous DNA 
sequences. In this way, we identified 8,837 A-to-G RNA editing sites and 3,965 RDD sites (Figure 
4.1a). 
Characteristics of RNA editing and RDD 
To verify that these 8,837 A-to-G editing sites are mediated by ADAR, we looked for 
well-known characteristics of ADAR editing. First, we found that 90% of our A-to-G editing sites 
are found in Alu elements, similar to the proportion seen in other studies (Wang et al., 2013). 
ADAR editing sites are often in non-coding regions. Seventy-seven percent (6,846) of the editing 
sites are found in 1,387 annotated genes. Of these 6,846 editing sites, 50% are found in introns, 
24% are found in 3’ UTRs, and less than 1% are found in coding regions. In addition, 66% of the 
genes that contain editing sites contain more than one editing site. There are an average of 5 A-
to-G editing sites per gene. In our dataset, the gene with the most editing sites is USP4 with 59 
editing sites. Furthermore, our A-to-G RNA editing sites show the same motif that has been 
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found by others to be targeted by ADAR (depletion of 5’ G and enrichment of 3’ G) (Figure 
4.1b). 
RNA editing sites have different characteristics compared to RDDs identified from the 
same RNA sequencing data. Using the same filtering steps, we identified 3,965 RDDs of the 
other 11 types of single-base differences (not including A-to-G). Only 51% of RDDs are found in 
Alu elements, compared to the 90% of A-to-G sites. 51% of RDDs are found in 1,339 annotated 
genes, of which 23% are in introns, 14% in 3’ UTRs, and 11% in coding regions. Many more 
RDDs are found in coding regions compared to A-to-G editing sites. Only 21% of genes 
containing an RDD show multiple RDDs, with an average of 2 RDDs per gene. 
Cis-regulation of RNA editing levels 
To study the relationship between editing sites, we focused on sites within genes that 
had at least five A-to-G editing sites. There are 2,373 A-to-G editing sites in 223 genes that met 
this criterion. We studied the correlation of editing levels across the ten individuals. For each of 
the 2,373 sites, we computed pairwise correlations for all sites in the same gene and averaged 
those correlation coefficients. We then permuted the data (10 permutations), preserving the 
number of sites per gene, and calculated correlation coefficients for the permuted data. We 
compared the correlations in the observed data with those from the permutations and found 
higher correlations among sites in the observed data (Figure 4.2a). Specifically, of the 223 genes 
studied, 131 genes showed higher correlations within the genes than compared to the 
randomized set. We narrowed our search to genes with sites that showed correlation 
coefficients of 0.1 and found that of the 66 genes to meet these criteria, 63 had greater 
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correlation of sites in the gene than to a random set. These data demonstrate that some genes 
show a correlation and suggest that sites in the same gene are similarly regulated. 
 We next wanted to delve further into the regulation of editing level by studying the 
correlation between sites in the same Alu element versus sites outside of the Alu element but 
all within the same gene. We focused our analysis on 231 editing sites in 25 genes that 
contained 2 edited Alu elements. We focused on these genes because of our knowledge of RNA 
secondary structure. It has been shown that Alu elements are common targets of ADAR editing 
due to their likelihood of creating double-stranded structures. Multiple Alu elements occurring 
in close proximity can create double-stranded structures due to high similarity of sequence. 
Therefore, we focused on the 25 genes with two Alu elements because we can assume that 
these two elements base-pair with each other to make an ADAR editing target. When we 
studied the 231 sites in 25 genes we found that there was a higher correlation of editing levels 
when comparing sites in the same Alu element as compared to other sites in the same gene but 
not found in the same Alu element (Figure 4.2b). Specifically, we found that 14 out of the 25 
genes had sites that showed higher correlation to other sites in the same Alu. While this group 
of 25 genes has only 2 edited Alu elements, it may have more Alu elements that are unedited 
and influence the secondary structure. We focused on 8 genes that had only 2 or 3 Alu 
elements in total in the region and found that 6 out of the 8 genes had higher correlation of 
sites in the same Alu than between. These findings suggest that sites in the same Alu elements 
have more similar editing levels. Furthermore, these data allow us to deduce that ADAR editing 
occurs along a given Alu and thereby along a single side of a double-stranded RNA region rather 
than on both sides simultaneously.  
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 As an example of this relationship between sites, we focused on one gene, ATG14, 
which has five editing sites spread across two Alu elements in its 3’UTR. Two of its five editing 
sites are correlated while the other three are correlated to each other, creating two groups of 
correlated sites. The first two appear in one Alu element and the rest in the other Alu element 
located in the 3’UTR of ATG14. The two Alu elements are predicted to make a long double-
stranded RNA secondary structure (Lorenz et al., 2011) with the first Alu on one side of the 
structure and the second Alu on the opposite side of the hairpin (Figure S4.2). This structure, 
with the correlations, suggest that sites in the same Alu element have more similar editing 
levels, and that ADAR edits one side of a hairpin structure at a time. Further study of editing 
level correlations may aid in the prediction of RNA secondary structure. 
Individual variation in RNA editing levels 
  We found that many A-to-G editing sites show evidence of variability in editing level 
across individuals. 40% of editing sites show a greater than 5-fold range in editing level across 
the ten individuals (Figure 4.3a). We therefore utilized this variability to understand more about 
the regulation of RNA editing. 
 Due to the large amount of variability in editing level across our ten unrelated 
individuals, we studied the possible genetic effects that could regulate ADAR editing. We began 
by studying ten sets of monozygotic twins. RNA was collected from B-cells derived from these 
20 individuals. The RNA was then sequenced. Using these data, we studied 4,498 A-to-G editing 
sites that were covered by at least 5 RNA reads in each of the 20 individuals. We then 
compared that variation within each twin pair to the variation in editing level between each 
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twin pair using the intraclass correlation analysis. Using this test, we identified 372 editing sites 
that show less variation within a twin pair than between pairs (ANOVA p-value < 0.01, ICC > 
0.66) (Figure 4.3b-c, Table S4.2). For the sites that have highly similar levels among monozygotic 
twins, we asked if they are genetically regulated by carrying out association analyses. 
Effect of genomic variation on RNA editing 
 We focused on 372 editing sites that showed significantly (p-value < 0.01) similar editing 
levels within twin pairs and performed association analyses. Of the 372 editing sites, there are 
54 sites that were found to have a previously identified SNP in the same gene that was covered 
by RNA-sequencing in all 20 individuals. These 54 sites were compared to a total of 51 SNPs in 
25 genes. We compared each SNP to any A-to-G editing site in the same gene leading to 116 
comparisons. 
 We identified 11 A-to-G editing sites that showed allelic association of SNP genotype to 
editing level across the 20 individuals (p-value < 0.05)(Figure 4.3d-e, Table S4.3). These sites 
show a trend where editing may be affected by nearby sequencing variation. However, of these 
11 sites, none reach significance following Bonferroni correction for multiple testing. Additional 
individuals would give more power to detect these associations. 
SEC16A 
 We next determined if editing in a non-coding region plays a role in RNA processing and 
gene expression. To this end, we focused on an editing site in the gene SEC16A.   
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 SEC16A encodes a protein involved in the marking of endoplasmic reticulum exit sites 
(ERES). These sites define where a vesicle will bud from the ER in order to transfer its contents 
to the Golgi apparatus (Watson et al., 2006). The 3’UTR of SEC16A contains an editing site 
(Figure 4.4a). Our first step was to verify that this editing site is mediated through ADAR RNA 
editing. To test this, we used data from previous work in our lab (Wang et al., 2013) where an 
ADAR knock-down was performed followed by RNA-sequencing. In these data, editing of this 
site is reduced from 3% to undetectable following knock-down of ADAR1 but not of ADAR2. This 
suggests that the editing site in SEC16A is indeed a target of ADAR1 RNA editing. 
Next we asked if the editing level of this site varies across tissues. We sequenced DNA 
and RNA from three different tissues (skeletal muscle, brain cortex, and liver) of three 
unrelated individuals. We verified that the DNA contained no evidence of guanosine at the 
SEC16A editing site in any of the three individuals. By studying the RNA from each of the tissues 
in the individuals, we found that RNA editing can be found in each of the nine samples (three 
tissues in three individuals) (Figure S4.3). We found that the editing levels at this site vary 
across individuals and across tissues. Across all three individuals, skeletal muscle shows the 
lowest editing levels of editing of the three tissues. 
Because the editing site in SEC16A is found in the 3’UTR, a region known to regulate 
RNA processing and decay, we asked if editing affects transcript stability. Previously, data from 
our lab showed that there is an interaction between ADAR and HuR (Wang et al., 2013), a 
protein that promotes the stability of mRNA transcripts (Peng et al., 1998). Kishore et al. 
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performed a CLIP-seq with HuR and identified several HuR binding sites in the vicinity of the 
RNA editing site in SEC16A (Kishore et al., 2011).  
To study if editing affects stability of SEC16A transcripts, we treated cells with 
actinomycin D and then collected RNA before treatment and 2, 4, 8, 12, and 24 hours after 
treatment. Sanger sequencing of these samples showed an increase in editing level over the 
time course (Figure 4.4b). These data suggest two potential scenarios. First, ADAR could be 
continuing to edit the pool of RNA and as the pool of RNA is gets smaller (as there is no active 
transcription), the editing level increases. The second possible reason for these results would 
be that the edited form of SEC16A is more stable and so as RNA is continually degraded, only 
the most stable transcripts remain, leading to an increased editing level. Since previous work 
has shown that HuR binds to SEC16A transcripts, the second scenario can be explained by HuR 
binding and stabilizing the edited transcripts.  
To investigate this possibility, we performed an RNA immunoprecipitation of HuR to 
determine whether it bound to the edited region of SEC16A in our B-cells. We verified binding 
of HuR to SEC16A (Figure S4.4). Using droplet digital PCR (Bio-Rad), we compare the number of 
droplets with edited transcripts to the total number of droplets with any SEC16A transcript to 
calculate the editing level of each sample. Using these data, we found that the edited transcript 
was enriched in the HuR-bound RNA (Figure 4.4c, Figure S4.5). While these data suggest that 
HuR may interact with edited transcripts of SEC16A, further study will help to elucidate whether 
editing plays a role in transcript stability or if the results following actinomycin treatment are 
caused by continual ADAR editing.  
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Conclusions 
 By studying RNA sequences from ten unrelated individuals, we identified 12,802 
locations in the transcriptome where the RNA did not match the corresponding DNA sequence. 
8,837 of these sites showed an adenosine in the DNA and a guanosine in the RNA suggesting a 
canonical ADAR-mediated RNA editing site. The A-to-G editing sites show features typical of 
ADAR editing, including 90% being located in Alu elements. These sites also have the motif 
associated with ADAR editing, including enrichment of guanosine downstream of the edited 
adenosine and depletion of guanosine one base upstream. Once we had identified the ADAR 
targets, we then characterized further the canonical A-to-G editing sites. 
 We found that over 30% of A-to-G editing sites show at least a 5-fold difference 
between the highest and lowest editing levels among the ten individuals. We decided to utilize 
this variability to learn about the regulation of RNA editing. We found that sites within the 
same Alu element and the same gene show higher correlation of editing levels.  
 To delve further into the regulation of editing, we studied ten twin pairs to determine 
heritability of editing levels. We identified 372 editing sites that had a significant intraclass 
correlation coefficient (p-value < 0.01), thereby suggesting a heritable factor that regulates 
gene expression. To search for this heritable factor, we studied single-nucleotide 
polymorphisms (SNPs) to determine association with editing level. We identified 11 sites that 
had editing levels associated with SNPs in the same gene across 20 individuals. Our data leads 
us to conclude that variability in RNA editing level can be affected by genomic variation in cis. 
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 Finally, we decided to examine one editing site more closely. We focused on an editing 
site in the 3’UTR of SEC16A. Editing of this site may help to regulate transcript stability through 
influencing binding of HuR. This demonstrates a way by which a variably edited site may lead to 
differences in the cell, such as transcript stability, among individuals. 
Further work should be done to expand the number of individuals as this will allow for 
an increase in power to detect associations and correlations among SNP genotypes and editing 
levels. Studying the twin sequencing data and identifying sites that show greater similarity in 
editing level within a twin pair than between suggests that our editing levels are accurately 
measured. However, replicating the sequencing of each sample would further verify accuracy of 
editing levels.  
 Together, this work sheds light on the regulation of ADAR editing transcriptome-wide, 
demonstrating that regulation of ADAR editing can be due to cis-acting elements, and helps 
elucidate the interaction of editing with RNA-binding proteins, such as HuR. 
Methods 
Cell culture: B-cells 
Cultured B-cells from monozygotic twins and individuals in the CEPH-Utah collection 
(Dausset et al., 1990) were used (Table S4.1). B-cells were cultured at a density of 5 x 105 
cells/mL in RPMI 1640 with 15% fetal bovine serum, 100 units/mL penicillin-streptomycin and 
2mM L-glutamine. Each batch was cultured separately. 
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RNA-sequencing and Analysis 
RNA-seq from B-cells was performed as recommended by the manufacturer (Illumina). 
RNA was extracted from the cultured B-cells using Qiagen RNeasy purification kits. The quality 
of the RNA was measured using the Agilent BioAnalyzer, and only those with RIN > 9.0 were 
used in the study. cDNA was made using Illumina TruSeq library construction kits. Briefly, RNA 
was first denatured, then fragmented and first and second strand synthesis was performed 
using oligo-dT primers. Adapters were added to the cDNA and samples were PCR amplified. The 
libraries were sequenced on a Hi-Seq instrument to synthesize 100bp reads (for original ten 
individuals and the individuals from the ten twin pairs) and 50bp (for 28 additional samples) 
(Illumina, San Diego, USA). 
The resulting sequences were analyzed as follows. Low quality bases (Phred-score ≤2) at 
the 3’ ends of reads were trimmed prior to alignment of the reads to the human reference 
genome (hg18) using GSNAP (version 2012.01.11, Wu and Nacu, 2010), and the following 
parameters: number of mismatches ≤ [(read length+2)/12-2], mapping score ≥ 20, soft-clipping 
on (trim mismatch score = -3), known exon-exon junctions as defined by RefSeq, Gencode 
(version 3c) and novel junctions as defined by GSNAP. SNP tolerant alignment was used with 
SNPs from the CEU population of HapMap (release #28, International HapMap Consortium 
2003) and 1000 genomes (pilot project, The 1000 Genomes Project Consortium 2010). Only 
reads that aligned to only one genomic locations were used. Gene expression was quantified 
using Cufflinks v2.1.1.  
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DNA-sequencing and Analysis 
DNA-seq of 4 of the original 10 individuals (GM10838, GM10839, GM12877, and 
GM12878) was performed as recommended by the manufacturer (Illumina). DNA was extracted 
from cultured B-cells followed by preparation of DNA-sequencing libraries using the Illumina 
TruSeq Paired-End construction kits. Briefly, DNA is fragmented, adapters are ligated onto each 
fragment and fragments are amplified via PCR. The libraries were sequenced on a HiSeq 
instrument to generate paired-end 100 bp reads. 
Low quality bases at the 3’ ends of reads were trimmed. The resulting reads were 
aligned to the human reference genome (hg18) using GSNAP. The following parameters were 
used for mapping: number of mismatches ≤ [(read length+2)/12-2], mapping score ≥ 20, and 
soft-clipping on (trim mismatch score = -3). Only reads that aligned to only one genomic 
locations were used. 
Identifying RDD and RNA editing sites 
To identify RNA-DNA Differences and RNA editing sites we compared the RNA-
sequencing reads to the reference human genome (hg18). To be included as an RNA editing site 
or RDD for a given sample, a site had to pass multiple criteria: 1) 10 total reads from RNA-seq, 
2) 2 reads (5% of the total reads at position) contained the a base that differs from the 
corresponding DNA sequence, 3) if within an intron, the site must be greater than 10 base pairs 
from the intron-exon junction, 5) site is not considered a SNP by dbSNP (build 138), 1000 
genomes or Exome Sequencing Project, and 6) no RDD read is found in any of the 4 DNA 
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samples. Additionally, the final list comprises of sites that are found in at least 10 out of the 30 
samples whose RNA was sequenced. 
In order to ensure uniqueness of RDD and RNA editing sites, further filtering steps were 
implemented. All sites found in pseudogenes (as annotated by RefSeq) and repetitive regions 
(RepeatMasker) except Alu elements were removed. Next, the genomic regions around each 
site (in 25bp, 50bp and 75bp each direction) must be unique as determined by mapping with 
local sequence alignment (BLAT). Sites were removed if BLAT revealed an alternative alignment 
with 3 or fewer mismatches. To ensure accurate mapping of RNA-sequencing reads, each read 
containing the RDD/edited form of the transcript was aligned using a local sequence aligner 
(BLAT). For a site to be included, over 50% of the RDD/edited reads must align to the same 
position with BLAT as with GSNAP. 
To ensure that the genomic sequence is homozygous across individuals, we used 
sequencing data from 99 CEU individuals (the same population as the 10 in our dataset) in the 
1000 Genomes collection. We required 1) that there be at least 10 reads covering the site 
among the 99 individuals (only 3 sites were removed by this requirement) and 2) that less than 
1% of reads contain the alternative allele. 1% of reads were allowed to contain the alternative 
allele due to the fact that many sites had over 500 reads and so we must allow for sequencing 
error. Furthermore, the DNA was sequenced to 30x coverage for 4 of our 10 individuals (as 
described above). If any RNA editing site showed even a single read containing the alternative 
allele from these four DNA-sequencing datasets, it was removed.  
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Validation of SEC16A by Sanger Sequencing 
 cDNA was prepared using the Taqman Reverse Transcription kit according to 
manufacturer’s protocol (Applied Biosystems). To validate the editing site in SEC16A (chr9: 
138455418) and the SNP two bases away (chr9:138455420), the region was amplified using PCR 
(Forward: 5’-ACCTGGCTGAATGAGTGGAG, Reverse: 5‘-AAAATCACCCATGGTCCTCA). The samples 
were denatured at 94°C for 3 min then put through a cycle of 45 seconds at 94°C, 45 seconds at 
55°C and 1 minute at 72°C for 40 cycles followed by 10 minutes at 72°C. PCR product was then 
purified using Qiaquick PCR Purification Kit (Qiagen 28106) and sequenced using the primers 
listed above. 
Human Tissue Samples 
Human skeletal muscle, liver tissue and brain cortex were obtained from the National 
Disease Research Interchange from three individuals (64998, 65080, and 65288). Tissues were 
collected between seven and twelve hours post-mortem during autopsies of donors that 
suffered from cardiac failure or respiratory failure. Individuals were between 62 and 79 years of 
age. Samples were snap-frozen and kept at -80°C. DNA was extracted from all tissue types using 
Puregene Tissue Kit (Qiagen). RNA was extracted from the skeletal muscle using RNeasy Maxi 
Kit (Qiagen), from liver using RNeasy Lipid Tissue Mini Kit (Qiagen) and from brain cortex using 
MaXtract High Density Kit (Qiagen). RNA was reverse transcribed, PCR amplified and sequenced 
as described in the previous section. 
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Treatment with Actinomycin D 
 B-cells were seeded at 500,000 cells/mL for eight to twelve hours, then they were 
treated with 5 µg/mL Actinomycin D (Sigma A-1410) that was dissolved in DMSO. Cells were 
collected before treatment and at the following time points 1, 2, 4, 8, 12, and 24 hours post 
treatment with Actinomycin D. DNA and RNA was extracted using AllPrep DNA/RNA Mini Kit 
(Qiagen 80204). RNA was reverse transcribed as described above. Genomic DNA and cDNA 
were PCR amplified using primers specific to SEC16A and sequenced as described above. 
ddPCR of SEC16A editing 
 Taqman assays were prepared (Applied Biosystems) to amplify the selected region of 
SEC16A (Forward: 5’-CCGAGGAGCCGTGGG, Reverse: 5’-TGCAACAGGAAAGAAATTCACTG) and 
probes were prepared correspond to the DNA and edited form of the transcript. The probe 
specific to the edited form of the transcript (5’-AGGCCCTGGTTACTG) was labeled with FAM 
while the probe specific to the unedited (DNA) form of the transcript (5’-
AGAGGCCCTAGTTACTG) was labeled with VIC. The PCR master mix was made by using cDNA or 
genomic DNA from the selected samples plus the two primers and two probes above and 
Taqman reagents. Emulsion PCR was then carried out according to manufacturer’s protocol 
(Bio-Rad Laboratories). PCR amplification conditions were 10 minutes at 95°C, followed by 40 
cycles of 30 seconds at 94°C and 1 minute at 57.6°C, followed by termination for 10 minutes at 
98°C. The fluorescent signal representing transcripts with either the unedited or edited base 
was then quantified using QuantaLife Droplet Reader (Bio-Rad Laboratories). 
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RNA Immunoprecipitation 
RNA immunoprecipitation was done using Magna RNA-Binding Protein 
Immunoprecipitation Kit (Millipore) per manufacturer’s protocol. Briefly, 40x106 B-cells were 
harvested and lysed with 200 µL of lysis buffer with protease and RNase inhibitors (cells were 
later split in half for HuR or IgG antibodies). 5 µg of anti-HuR (Millipore CS203212) or negative 
control rabbit IgG (Millipore PP64B) was conjugated to protein A/G beads. 100 µL of the original 
200 µL cell lysate was added to 900 µL immunoprecipitation buffer with RNase inhibitor and 
incubated with 50 µL of beads and appropriate antibody overnight at 4°C. Then, the beads and 
the bound immunoprecipitate were washed six times with wash buffer and RNase inhibitor and 
then incubated for 30 minutes at 55°C in protease K and 1% SDS. RNA was extracted from the 
supernatants using TriPure reagent (Roche 11667157001) and chloroform. The resulting RNA 
was reverse transcribed into cDNA as above and used to detect binding of SEC16A by HuR using 
real-time PCR (Forward: 5’-CGCTGTGTTCTCAATCAGC, Reverse: 5’-
CAACAGGAAAGAAATTCACTGC). 
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Figure 4.1 
 
Figure 4.1: Characteristics of RNA editing sites and RDDs. A) Graph showing the number of RDD or 
editing sites of each type. B) Percentage of each base 10 bases upstream and downstream from A-to-G 
sites.  
  
 103 
 
Figure 4.2 
 
Figure 4.2: Correlation of editing levels of sites in the same transcript. A) Cumulative distribution 
function comparing the correlation of editing levels across 2,373 sites in the ten individuals. Red line 
indicates average correlation of sites in the same gene. Black lines indicate average correlation of the 
same number of random sites. Ten black lines denote ten permutations of random sites. B) Cumulative 
distribution function comparing the correlation of editing levels for 231 sites. Red indicates average 
correlations to other sites in the same Alu element while blue denotes average correlations of sites in 
the same gene but not in the same Alu element.  
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Figure 4.3 
 
Figure 4.3: Cis-association of editing levels. A) Levels of A-to-G editing at ten sites in ten, unrelated 
individuals. Each point denotes one individual. B-E) Editing levels at two sites (MDM2 at chr12:67523320 
and INPP5B at chr1:38099287). B-C) Editing levels across 10 twin pairs with each point denoting the 
editing level of one individual. ICC of site in MDM2 is 0.84 and ICC of INPP5B is 0.72. D-E) Editing level 
from the 20 individuals used for association analysis including one individual from each twin pair and the 
10 original individuals (ANOVA, for MDM2 and INPP5B p-values are <0.005 and <0.05, respectively). 
Each point denotes editing level of one individual. 
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Figure 4.4 
 
Figure 4.4: RNA editing of SEC16A. A) Sanger sequencing trace of editing site at chr9:138,455,418. 
Genomic and cDNA derived from the same individual, individual 1 (GM11994). B) Sanger sequencing of 
the same region as A) following time course of Actinomycin D in GM11831. C) HuR RNA-
immunoprecipitation results for two individuals (Individual 1 – GM11994, Individual 2 – GM12716) are 
denoted in the graph. Percentage of edited allele was found for the HuR RNA-IP fraction and the input 
sample by ddPCR and shown in the graph. 
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Table S4.1: RNA-sequencing datasets. 
Original 10 Individual Twin Pairs 
GM07000 Pair 1: GM14831 
GM10838 Pair 1: GM14832 
GM10839 Pair 2: GM14408 
GM11992 Pair 2: GM14409 
GM11993 Pair 3: GM14432 
GM11994 Pair 3: GM14433 
GM12716 Pair 4: GM14447 
GM12717 Pair 4: GM14448 
GM12877 Pair 5: GM14452 
GM12878 Pair 5: GM14453 
  Pair 6: GM14467 
  Pair 6: GM14468 
  Pair 7: GM14506 
  Pair 7: GM14507 
  Pair 8: GM14520 
  Pair 8: GM14521 
  Pair 9: GM14568 
  Pair 9: GM14569 
  Pair 10: GM14581 
  Pair 10: GM14582 
 
Table S4.1: Two datasets were used in this paper as denoted in this table. For the association analysis, 
one individual from each twin pair (shown in bold) was used along with the original ten individuals. 
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Table S4.2: Editing sites with significant ICC. 
Chrom Position Gene Name P-values (ANOVA) ICC 
1 1243644 CPSF3L 2.13E-03 0.76 
1 1585423 CDK11B 5.15E-03 0.71 
1 7900815 TNFRSF9 7.42E-03 0.69 
1 17614868 RCC2 1.77E-03 0.77 
1 20954404 HP1BP3 7.62E-03 0.68 
1 20954546 HP1BP3 1.71E-04 0.86 
1 35840512 PSMB2 2.31E-03 0.76 
1 38099181 INPP5B 4.91E-03 0.71 
1 38099287 INPP5B 4.63E-03 0.72 
1 38100287 INPP5B 4.61E-03 0.72 
1 45015565 RPS8 4.49E-03 0.72 
1 54337885 TCEANC2 8.36E-03 0.68 
1 78115317 FAM73A 4.33E-03 0.72 
1 78880781 IFI44L 2.93E-14 1.00 
1 85170094 MCOLN2 1.79E-03 0.77 
1 85170195 MCOLN2 9.56E-04 0.80 
1 85170289 MCOLN2 4.63E-04 0.83 
1 85170620 MCOLN2 6.21E-03 0.70 
1 93573001 LOC100131564 4.25E-03 0.72 
1 93576124 LOC100131564 1.96E-03 0.77 
1 93576210 LOC100131564 3.00E-05 0.90 
1 100262423 N/A 9.66E-03 0.67 
1 117426856 TTF2 7.13E-04 0.81 
1 153551677 FDPS 3.69E-04 0.84 
1 165940932 RCSD1 1.31E-12 1.00 
1 177592486 N/A 8.16E-03 0.68 
1 177593631 N/A 7.66E-03 0.68 
1 177593634 N/A 9.97E-03 0.66 
1 202787065 MDM4 8.59E-03 0.68 
1 202791169 MDM4 1.95E-03 0.77 
1 206008959 CD46 6.32E-03 0.70 
1 206008966 CD46 2.69E-03 0.75 
2 24076663 UBXN2A 1.74E-04 0.86 
2 39555485 LOC728730 7.37E-04 0.81 
2 85403736 TGOLN2 2.13E-03 0.76 
2 113050712 POLR1B 8.50E-07 0.95 
2 171886747 METTL8 1.88E-03 0.77 
2 179006651 MIR548N 1.31E-03 0.79 
2 198064890 HSPD1 3.52E-03 0.73 
2 198064915 HSPD1 5.77E-03 0.70 
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2 198069877 HSPD1 3.98E-03 0.73 
2 201550806 FAM126B 7.42E-03 0.69 
2 201550814 FAM126B 1.15E-03 0.79 
2 201740214 CFLAR 2.71E-03 0.75 
2 216611743 PECR 6.08E-03 0.70 
2 218808332 ARPC2 7.57E-03 0.68 
2 218808394 ARPC2 7.11E-04 0.81 
2 218808418 ARPC2 1.19E-03 0.79 
2 218808823 ARPC2 5.34E-06 0.93 
2 218808824 ARPC2 3.82E-03 0.73 
2 218808911 ARPC2 4.08E-03 0.73 
2 218809372 ARPC2 4.44E-03 0.72 
2 223132588 N/A 5.82E-03 0.70 
2 223132607 N/A 5.99E-03 0.70 
2 224329272 AP1S3 1.03E-03 0.80 
2 241912658 SEPT2 2.67E-03 0.75 
3 10167825 VHL 4.85E-03 0.71 
3 10169555 VHL 4.11E-03 0.73 
3 10169706 VHL 7.09E-03 0.69 
3 10169983 VHL 1.50E-04 0.87 
3 10169984 VHL 7.89E-04 0.81 
3 10169988 VHL 4.67E-03 0.72 
3 15426906 METTL6 4.03E-03 0.73 
3 38541028 EXOG 1.32E-03 0.79 
3 40553935 ZNF621 9.72E-03 0.67 
3 45697104 LIMD1 2.67E-04 0.85 
3 50109312 RBM5 8.48E-03 0.68 
3 122840500 HCLS1 9.36E-03 0.67 
3 137533573 N/A 7.03E-03 0.69 
3 143151628 TFDP2 4.76E-04 0.83 
3 157741923 SSR3 1.92E-04 0.86 
3 188100875 N/A 7.73E-05 0.88 
4 116769 ZNF718 4.58E-03 0.72 
4 57020883 PAICS 3.30E-03 0.74 
4 57020916 PAICS 2.09E-03 0.76 
4 57021090 PAICS 1.92E-04 0.86 
4 57021632 PAICS 2.67E-04 0.85 
4 57021636 PAICS 6.43E-04 0.82 
4 71892206 RUFY3 7.96E-06 0.93 
4 84036824 LOC100499177 2.18E-03 0.76 
4 191120826 FRG1 1.93E-04 0.86 
5 1531060 LPCAT1 9.38E-04 0.80 
5 34989203 DNAJC21 4.18E-03 0.72 
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5 40861693 LOC100506548 8.38E-03 0.68 
5 43417357 CCL28 3.24E-03 0.74 
5 74710543 COL4A3BP 3.40E-04 0.84 
5 74710678 COL4A3BP 2.28E-03 0.76 
5 125990381 PHAX 8.20E-04 0.81 
5 130523546 HINT1 7.77E-03 0.68 
5 130523712 HINT1 9.66E-03 0.67 
5 130523736 HINT1 7.06E-03 0.69 
5 130565567 LYRM7 1.41E-05 0.92 
5 130565823 LYRM7 8.16E-04 0.81 
5 130565975 LYRM7 1.07E-03 0.80 
5 130567745 LYRM7 1.98E-03 0.77 
5 131836275 C5orf56 1.66E-03 0.78 
5 150627930 GM2A 2.92E-03 0.75 
5 179199904 C5orf45 2.65E-03 0.75 
5 179199915 C5orf45 4.18E-03 0.72 
5 179200010 C5orf45 3.10E-03 0.74 
6 32549218 N/A 2.67E-05 0.91 
6 33080993 HLA-DOA 7.97E-04 0.81 
6 33081005 HLA-DOA 9.52E-03 0.67 
6 33081401 HLA-DOA 5.87E-04 0.82 
6 33081535 HLA-DOA 7.09E-04 0.81 
6 33081553 HLA-DOA 1.71E-03 0.77 
6 33484523 KIFC1 8.39E-03 0.68 
6 42153541 TAF8 8.08E-03 0.68 
6 42155340 TAF8 5.57E-03 0.71 
6 43691647 POLH 4.69E-03 0.72 
6 43692054 POLH 6.87E-03 0.69 
6 43693170 POLH 9.83E-04 0.80 
6 53265496 ELOVL5 1.28E-05 0.92 
6 57030260 N/A 6.04E-03 0.70 
6 109892696 ZBTB24 5.48E-03 0.71 
6 149811911 ZC3H12D 5.78E-03 0.70 
6 150087691 NUP43 8.82E-03 0.67 
6 167271993 RNASET2 6.24E-03 0.70 
7 17351405 AHR 7.97E-03 0.68 
7 17351412 AHR 3.14E-04 0.84 
7 20144144 MACC1 4.30E-03 0.72 
7 20144152 MACC1 6.91E-03 0.69 
7 20144179 MACC1 2.51E-03 0.75 
7 20144193 MACC1 9.98E-04 0.80 
7 44807913 PPIA 5.63E-03 0.71 
7 44808044 PPIA 1.93E-03 0.77 
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7 44808624 PPIA 6.79E-03 0.69 
7 44839012 H2AFV 1.93E-03 0.77 
7 44839264 H2AFV 5.11E-04 0.83 
7 44839352 H2AFV 5.16E-03 0.71 
7 56088661 CCT6A 1.91E-03 0.77 
7 65255714 CRCP 5.75E-03 0.70 
7 73275649 LAT2 5.94E-04 0.82 
7 73284232 RFC2 8.79E-05 0.88 
7 86654508 DMTF1 1.07E-03 0.80 
7 89857309 GTPBP10 1.13E-05 0.92 
7 100521478 N/A 1.49E-03 0.78 
7 128080669 FLJ45340 8.96E-06 0.93 
7 128086502 FLJ45340 8.29E-03 0.68 
7 130280164 FLJ43663 6.71E-04 0.82 
7 130280166 FLJ43663 1.79E-05 0.91 
7 130280532 FLJ43663 3.36E-03 0.74 
7 149766473 LOC285972 1.66E-03 0.78 
7 149766499 LOC285972 3.15E-03 0.74 
8 30655694 GSR 8.84E-03 0.67 
8 30655952 GSR 6.87E-03 0.69 
8 38948894 PLEKHA2 3.76E-03 0.73 
8 38948932 PLEKHA2 6.33E-03 0.70 
8 38948996 PLEKHA2 1.40E-04 0.87 
8 38949002 PLEKHA2 8.98E-04 0.80 
8 38949743 PLEKHA2 7.73E-03 0.68 
8 66805472 PDE7A 5.39E-04 0.82 
8 99125087 RPL30 5.11E-03 0.71 
8 99125514 RPL30 1.03E-03 0.80 
8 142221069 DENND3 9.70E-03 0.67 
8 144808685 N/A 7.12E-03 0.69 
9 6708349 N/A 8.44E-05 0.88 
9 37493392 POLR1E 1.03E-03 0.80 
9 131713235 FNBP1 2.60E-03 0.75 
9 131716139 FNBP1 6.43E-03 0.70 
9 131717541 FNBP1 5.61E-03 0.71 
9 131725162 FNBP1 8.82E-03 0.67 
9 131725249 FNBP1 2.04E-04 0.86 
9 132570300 N/A 6.70E-03 0.69 
9 132571724 N/A 6.39E-03 0.70 
9 138455418 SEC16A 4.13E-03 0.73 
10 70189289 CCAR1 8.59E-03 0.68 
10 73663789 ANAPC16 8.86E-03 0.67 
10 74679850 MRPS16 6.23E-03 0.70 
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10 75206082 N/A 8.50E-04 0.81 
10 75206083 N/A 5.27E-03 0.71 
10 75206178 N/A 1.75E-03 0.77 
10 75206298 N/A 4.08E-03 0.73 
10 75206318 N/A 2.02E-04 0.86 
10 75206324 N/A 8.55E-03 0.68 
10 75206464 N/A 4.82E-03 0.72 
10 75207418 N/A 6.19E-03 0.70 
10 96360520 N/A 4.15E-03 0.72 
10 101982673 CWF19L1 2.14E-03 0.76 
10 103537618 MGEA5 2.18E-03 0.76 
10 103561417 MGEA5 2.27E-03 0.76 
10 134927644 ADAM8 9.54E-03 0.67 
11 759779 PDDC1 4.26E-03 0.72 
11 31409161 DNAJC24 4.25E-06 0.94 
11 33052850 N/A 2.68E-04 0.85 
11 33053606 N/A 2.01E-03 0.77 
11 62263887 N/A 5.17E-03 0.71 
12 9732528 CLEC2D 3.35E-03 0.74 
12 9732535 CLEC2D 3.28E-03 0.74 
12 14543879 N/A 3.46E-05 0.90 
12 27078716 N/A 1.38E-05 0.92 
12 27078903 N/A 2.71E-03 0.75 
12 27079281 N/A 4.15E-04 0.83 
12 27079369 N/A 3.14E-03 0.74 
12 27465468 N/A 1.56E-03 0.78 
12 27465694 N/A 1.55E-04 0.87 
12 27838791 KLHDC5 6.69E-03 0.69 
12 47618511 ARF3 2.09E-03 0.76 
12 63130434 N/A 6.29E-03 0.70 
12 67523271 MDM2 5.03E-03 0.71 
12 67523309 MDM2 3.29E-04 0.84 
12 67523310 MDM2 2.75E-08 0.98 
12 67523320 MDM2 3.92E-04 0.84 
12 67523773 MDM2 6.27E-03 0.70 
12 67523786 MDM2 4.04E-04 0.83 
12 97467164 TMPO 1.38E-07 0.97 
12 109420433 VPS29 3.26E-03 0.74 
12 112203790 TPCN1 3.76E-05 0.90 
12 112313307 N/A 3.58E-04 0.84 
12 112313308 N/A 1.92E-03 0.77 
12 117059632 PEBP1 5.88E-04 0.82 
12 119383458 GATC 6.36E-03 0.70 
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12 120256202 ANAPC5 3.73E-03 0.73 
12 122675039 EIF2B1 6.35E-03 0.70 
12 131807977 PGAM5 6.89E-04 0.81 
12 131808168 PGAM5 3.24E-05 0.90 
12 131808194 PGAM5 3.03E-03 0.74 
13 20846502 ZDHHC20 3.85E-06 0.94 
13 20847107 ZDHHC20 1.27E-03 0.79 
13 44988372 COG3 5.48E-04 0.82 
13 110349045 ANKRD10 1.55E-03 0.78 
14 19905128 TEP1 4.49E-03 0.72 
14 23983669 N/A 2.70E-03 0.75 
14 34564938 SRP54 5.25E-03 0.71 
14 52312609 GNPNAT1 2.86E-03 0.75 
14 54592126 MAPK1IP1L 1.92E-03 0.77 
14 54597427 MAPK1IP1L 4.68E-03 0.72 
14 54904719 ATG14 2.28E-03 0.76 
14 90752682 C14orf159 1.23E-05 0.92 
14 103231015 KLC1 5.93E-03 0.70 
15 39384939 N/A 4.21E-03 0.72 
15 39384949 N/A 5.96E-05 0.89 
15 40647240 HAUS2 1.01E-03 0.80 
15 48447516 N/A 5.15E-04 0.83 
15 62234026 SNX22 1.10E-03 0.79 
15 73433139 NEIL1 2.45E-03 0.76 
15 83440922 PDE8A 1.26E-03 0.79 
16 11836425 RSL1D1 9.23E-04 0.80 
16 11836984 RSL1D1 6.18E-03 0.70 
16 13949951 ERCC4 5.68E-03 0.70 
16 15701474 NDE1 1.03E-03 0.80 
16 15701825 NDE1 2.73E-04 0.85 
16 15701988 NDE1 7.25E-04 0.81 
16 15702345 NDE1 6.25E-03 0.70 
16 15702536 NDE1 7.10E-07 0.96 
16 22204361 EEF2K 2.58E-04 0.85 
16 22204439 EEF2K 9.69E-03 0.67 
16 27369486 IL21R 5.02E-03 0.71 
16 27370394 IL21R 2.10E-03 0.76 
16 28751005 ATXN2L 2.73E-04 0.85 
16 29586447 SPN 3.03E-03 0.74 
16 29587051 SPN 1.31E-04 0.87 
16 29587323 SPN 3.33E-03 0.74 
16 29587522 SPN 9.34E-03 0.67 
16 29587532 SPN 4.30E-05 0.90 
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16 29587784 SPN 3.54E-05 0.90 
16 29587918 SPN 5.78E-03 0.70 
16 29588423 SPN 2.09E-03 0.76 
16 29753224 MVP 8.05E-03 0.68 
16 46945855 MIR548AE2 7.96E-03 0.68 
16 55647735 NLRC5 1.25E-03 0.79 
16 55648552 NLRC5 4.30E-03 0.72 
16 79620781 CENPN 7.82E-03 0.68 
16 83258175 N/A 2.40E-03 0.76 
16 88157407 RPL13 6.68E-04 0.82 
16 88157527 RPL13 7.23E-04 0.81 
17 2268356 METTL16 3.52E-04 0.84 
17 3524357 P2RX5 5.84E-03 0.70 
17 3525364 P2RX5 1.88E-03 0.77 
17 4869087 KIF1C 3.87E-03 0.73 
17 31178703 TAF15 7.35E-03 0.69 
17 40575770 ACBD4 7.73E-03 0.68 
17 44296677 CALCOCO2 2.42E-03 0.76 
17 46397215 SPAG9 1.52E-03 0.78 
17 54635387 PRR11 8.44E-04 0.81 
17 59910467 POLG2 1.70E-03 0.77 
17 71397599 TRIM65 1.93E-05 0.91 
17 71451828 ACOX1 8.16E-03 0.68 
17 73617255 LOC100131096 6.70E-03 0.69 
17 73930206 PGS1 8.12E-03 0.68 
17 73930313 PGS1 6.74E-03 0.69 
18 54569458 N/A 3.85E-03 0.73 
19 2031647 MOBKL2A 1.20E-03 0.79 
19 3491316 C19orf28 1.60E-03 0.78 
19 4605537 TNFAIP8L1 8.18E-04 0.81 
19 4605554 TNFAIP8L1 5.72E-03 0.70 
19 5660146 LONP1 9.33E-03 0.67 
19 7665229 FCER2 6.10E-03 0.70 
19 7665859 FCER2 8.32E-03 0.68 
19 7666681 FCER2 6.98E-04 0.81 
19 7666958 FCER2 4.60E-03 0.72 
19 7667260 FCER2 5.14E-03 0.71 
19 10889920 CARM1 2.24E-03 0.76 
19 13744855 MRI1 2.18E-03 0.76 
19 13744923 MRI1 9.32E-03 0.67 
19 13745419 MRI1 8.55E-03 0.68 
19 14569513 CLEC17A 5.55E-04 0.82 
19 14569530 CLEC17A 1.66E-03 0.78 
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19 14582497 CLEC17A 1.97E-04 0.86 
19 14582498 CLEC17A 2.70E-05 0.91 
19 14582553 CLEC17A 7.71E-04 0.81 
19 14582594 CLEC17A 4.79E-03 0.72 
19 18337948 PGPEP1 1.05E-03 0.80 
19 18338312 PGPEP1 2.28E-03 0.76 
19 18338815 PGPEP1 1.32E-03 0.79 
19 18338901 PGPEP1 3.27E-04 0.84 
19 18530846 C19orf50 1.46E-05 0.92 
19 19653335 N/A 3.70E-03 0.73 
19 19653408 N/A 8.45E-04 0.81 
19 21266341 ZNF708 5.77E-04 0.82 
19 40512956 CD22 1.07E-03 0.80 
19 40513928 CD22 4.63E-03 0.72 
19 40514342 CD22 2.05E-03 0.76 
19 40517474 CD22 1.40E-03 0.78 
19 41729014 ZNF529 4.42E-04 0.83 
19 44050992 RINL 9.47E-04 0.80 
19 44674071 N/A 5.57E-03 0.71 
19 57898485 ZNF611 8.68E-03 0.67 
19 58689888 N/A 6.07E-04 0.82 
19 58689956 N/A 4.49E-03 0.72 
19 62508825 N/A 9.46E-03 0.67 
19 62960197 ZNF776 6.30E-03 0.70 
19 63046861 LOC100293516 4.04E-03 0.73 
19 63046881 LOC100293516 8.59E-03 0.68 
19 63070149 N/A 6.84E-03 0.69 
19 63785572 MGC2752 1.97E-03 0.77 
19 63787385 MGC2752 3.37E-04 0.84 
20 3796078 MAVS 2.75E-04 0.85 
20 3796188 MAVS 5.87E-03 0.70 
20 3798191 MAVS 1.54E-03 0.78 
20 3801067 MAVS 3.99E-04 0.84 
20 33681293 CPNE1 5.34E-03 0.71 
20 33681371 CPNE1 9.88E-03 0.66 
20 33764606 RBM39 1.69E-03 0.77 
20 33765106 RBM39 1.11E-03 0.79 
20 33765163 RBM39 2.54E-03 0.75 
20 43140284 STK4 5.72E-04 0.82 
20 43140402 STK4 7.24E-03 0.69 
20 43141123 STK4 1.76E-03 0.77 
20 44186067 CD40 3.88E-03 0.73 
21 29358242 CCT8 6.24E-03 0.70 
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21 33558893 N/A 4.45E-03 0.72 
21 34199188 ATP5O 5.10E-03 0.71 
21 43137033 WDR4 4.12E-03 0.73 
22 16951271 PEX26 7.70E-03 0.68 
22 17818564 UFD1L 2.36E-03 0.76 
22 22644046 DDT 4.02E-04 0.83 
22 22644078 DDT 1.31E-03 0.79 
22 22644094 DDT 4.13E-04 0.83 
22 22644147 DDT 4.40E-05 0.90 
22 22644244 DDT 1.90E-04 0.86 
22 23300542 N/A 5.35E-04 0.82 
22 24451085 ADRBK2 6.03E-03 0.70 
22 37744869 N/A 6.18E-03 0.70 
22 37745837 N/A 5.39E-03 0.71 
22 37752842 APOBEC3D 5.45E-03 0.71 
22 37759009 APOBEC3D 9.25E-06 0.93 
22 37779445 APOBEC3F 4.62E-03 0.72 
22 37779451 APOBEC3F 2.99E-04 0.85 
22 43969023 KIAA0930 4.04E-03 0.73 
X 156177 PLCXD1 5.32E-04 0.82 
X 156473 PLCXD1 6.28E-05 0.89 
X 157393 PLCXD1 8.17E-03 0.68 
X 157402 PLCXD1 1.10E-03 0.79 
X 157844 PLCXD1 1.07E-04 0.88 
X 157852 PLCXD1 4.32E-03 0.72 
X 157946 PLCXD1 9.24E-04 0.80 
X 158215 PLCXD1 9.68E-04 0.80 
X 24003875 EIF2S3 7.54E-03 0.68 
X 84232559 APOOL 2.97E-03 0.74 
X 118642447 SEPT6 1.40E-03 0.78 
X 118642993 SEPT6 2.78E-04 0.85 
 
Table S4.2: This table denotes editing sites with ICC > 0.66 across the ten twin pairs. 
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Table S4.3: Cis-associated editing sites across twenty individuals. 
Editing Site 
Position (hg18) 
Gene 
Name 
Genic Region 
of Editing Site 
SNP Position 
(hg18) 
SNP rs# P-values 
chr1:38099181 INPP5B 3'UTR chr1:38184032 rs871524 0.021 
chr1:38099287 INPP5B 3'UTR chr1:38184032 rs871524 0.019 
chr1:38100287 INPP5B 3'UTR chr1:38184032 rs871524 0.019 
chr12:67523309 MDM2 3'UTR chr12:67488431 rs937283 0.020 
chr12:67523310 MDM2 3'UTR chr12:67488431 rs937283 0.001 
chr12:67523320 MDM2 3'UTR chr12:67488431 rs937283 0.001 
chr16:88157407 RPL13 3'UTR chr16:88157812 rs12709089 0.026 
chr16:88157527 RPL13 3'UTR chr16:88157812 rs12709089 0.024 
chr20:3796188 MAVS 3'UTR chr20:3799600 rs34419413 0.015 
chr20:3796188 MAVS 3'UTR chr20:3801093 rs17212649 0.015 
chr20:3801067 MAVS 3'UTR chr20:3798968 rs14161 0.034 
 
Table S4.3: This table denotes editing sites with p-values < 0.05 from ANOVA across the twenty, 
unrelated individuals. 
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Figure S4.1 
 
Figure S4.1: Analysis for identification of RDDs among ten individuals. This flow-chart indicates the steps 
used to identify all RDDs and editing sites from the original ten individuals. 
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Figure S4.2 
 
Figure S4.2: ATG14: Example of RNA folding and editing. A) Gene structure for ATG14 with the five 
editing sites indicated. There are two groups of editing sites: 1) 54,904,950 and 54,904,986 and 2) 
54,904,115, 54,904,132 and 54,904,152 as indicated by the arrows (blue shows the first group, orange 
shows the second group). B) Heatmap indicating the correlation coefficient determined by comparing 
the editing levels of the indicated sites across ten, unrelated individuals. C) RNA secondary structure 
(Lorenz et al., 2011) with the editing sites indicated by arrows. 
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Figure S4.3 
 
Figure S4.3: Editing of SEC16A in three tissues. Sanger sequencing traces of editing site and C/T SNP at 
chr9:138,455,418 and 13,455,420, respectively. Genomic and cDNA derived from the same individuals 
(Individual 1 – 64998, Individual 2 – 65080, Individual 3 – 65288 from NDRI). 
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Figure S4.4 
 
Figure S4.4: HuR RNA-IP of SEC16A. HuR RNA-immunoprecipitation performed on two individuals 
(GM11994 and GM12716). Quantitative real-time PCR was performed to target SEC16A and the graph 
shows enrichment of this region in the HuR RNA-IP as compared to sample immunoprecipitated by IgG. 
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Figure S4.5 
 
Figure S4.5: HuR RNA-IP by ddPCR. Representative examples of ddPCR results comparing edited versus 
unedited transcripts in HuR RNA-immunoprecipitation samples from two individuals (Individual 1 – 
GM11994, Individual 2 – GM12716). Results comparing HuR RIP to input over four or three replicates 
(for GM11994 and GM12716, respectively) are denoted in the graph in Figure 4c (IgG is not utilized 
because few droplets contain any SEC16A transcript). Editing level was calculated for the HuR RNA-IP 
fraction, IgG RNA-IP fraction and the input sample by ddPCR by comparing the number of droplets with 
the edited transcript compared to the total number of droplets containing SEC16A transcripts. 
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Chapter 5: RNA Editing in Response to ER Stress in Human B-cells 
 
Abstract 
 Endoplasmic reticulum (ER) stress leads to many changes as the cell attempts to re-
establish homeostasis. ER stress is caused by an excess of misfolded proteins in the cell. This 
leads to changes in expression of genes involved in protein folding, transport and cell cycle to 
help the cell cope with the misfolded proteins. In this study, we show that certain RNA 
processing steps, including RNA editing, are also influenced by ER stress. We collected and 
sequenced RNA from B-cells of ten individuals before, and two and eight hours following ER 
stress induction. By comparing the RNA and corresponding DNA sequences, we identified over 
4,000 A-to-G editing sites among the ten individuals. A subset of these editing sites, found in 
genes important for the ER stress response, show changes in editing level following ER stress. 
Additionally, some of these sites have editing levels correlated to gene expression following ER 
stress. These data suggest that the changes in editing level may play a role in the ER stress 
response. In addition to changes in canonical A-to-G editing, we also find other types of single-
base differences that change level following ER stress. Our study demonstrates that RNA editing 
responds to ER stress and may play a role in the ER stress response. 
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Introduction 
The endoplasmic reticulum (ER) is an organelle that synthesizes and modifies proteins. 
ER stress occurs when there is an excess of misfolded proteins in the cell. It has been shown in 
previous studies that ER stress leads to gene expression changes in a wide variety of pathways 
from protein transport to cell cycle control (Dombroski et al., 2010). These changes in 
expression will either re-establish homeostasis or initiate apoptosis in cells. Changes in gene 
expression are influenced by a variety of mechanisms, including RNA processing steps such as 
RNA editing. We asked whether RNA editing and other RNA-DNA sequence Differences (RDD) 
were also affected by ER stress and how changes in these modes of RNA processing may 
influence expression of ER stress-responsive genes.  
One form of RNA editing in humans is mediated by Adenosine Deaminase Acting on RNA 
(ADAR) which results in thousands of A-to-G differences between the DNA and corresponding 
RNA sequences throughout the transcriptome (Athanasiadis et al., 2004, Levanon et al., 2004, Li 
et al., 2009, Wang et al., 2013). The best characterized examples of this type of RNA editing are 
found in coding regions of ion channels. These sites cause changes to the amino acid sequence 
and affect the channel permeability and function (Sommer et al., 1991, Lomeli et al., 1994, 
Seeburg et al., 1998). Though there are a handful of editing sites in coding sequences, many 
editing sites are in non-coding regions and are predicted to affect RNA expression. For example, 
studies have demonstrated that some RNA editing can affect RNA processing, such as splicing 
(Athanasiadis et al., 2004, Lev-Maor et al., 2007), transport (Zhang and Carmichael, 2001) and 
decay (Scadden 2005). In addition to canonical RNA editing, our lab has previously 
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characterized the other eleven types of single-base differences between the RNA and DNA. 
RDDs are also found throughout the transcriptome, in coding and non-coding regions of 
transcripts (Li et al., 2011).  
  In this study, we explore the role of RNA editing and RDDs in the ER stress response. We 
identified both canonical ADAR editing and RDD sites in genes involved in the ER stress 
response. Furthermore, a subset of these sites show changes in level following ER stress and 
the levels of editing correlate to changes in gene expression. This suggests that changes in 
editing and RDD level may play a role in the ER stress response. 
Induction of ER stress 
We induced ER stress in cultured human B-cells with tunicamycin. Tunicamycin induces 
ER stress by blocking N-glycosylation, which is necessary for proper protein folding (Tkacz and 
Lampen, 1975). We confirmed induction of ER stress by quantifying two steps in the unfolded 
protein response, XBP1 splicing and up-regulation of a protein chaperone, BiP (Yoshida et al., 
2001, Kozutsumi et al., 1988). ER stress is induced by tunicamycin in our human B-cells as 
shown by an increase in the spliced form of XBP1 following 2 hours of tunicamycin treatment 
and an increase in BiP expression following 8 hours of tunicamycin treatment (Figure 5.1a,b).  
Gene expression changes following ER stress 
 To study the response of B-cells to ER stress, we treated cells derived from ten 
unrelated individuals with tunicamycin. We collected RNA from before, and 2 and 8 hours 
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following treatment. We used RNA-sequencing of these 30 samples to characterize the gene 
expression and RNA editing response to ER stress.  
We identified 12,426 genes that were expressed (FPKM ≥ 1) in at least five of the 30 
samples. Of these genes, 4,182 genes showed significant changes in gene expression following 
2 or 8 hours of ER stress across the ten individuals (ANOVA, nominal p-value < 0.01) (Figure 
5.1c). 1,244 genes were significant even after Bonferroni correction. In order to learn about the 
ER stress response more comprehensively, we further analyzed the 4,182 genes that met the 
lower cut-off. At 2 hours after tunicamycin treatment, 2,012 genes showed changes in 
expression ranging from 27-fold increase to 4-fold decrease in expression (1,154 increase, 858 
decrease). Following 8 hours of ER stress, 3,580 genes changed expression from 31-fold 
increase to 11-fold decrease in expression (1,798 increase, 1,782 decrease). These groups are 
not exclusive as we see 1,530 changing at both time points (post hoc t-test, p < 0.01). Over 60 
genes had previously been characterized as ER stress-responsive genes (Ashburner et al., 2000, 
Gene Ontology Consortium 2015, GO:0034976). For example, EDEM1, a gene that is involved in 
ER-associated decay of proteins following ER stress, increases after 8 hours of tunicamycin 
treatment.To further characterize these expression changes, we performed hierarchical 
clustering on the 4,182 ER stress-responsive genes. These genes cluster into five groups that 
separate genes that upregulated or downregulated at 2 versus 8 hours following ER stress 
(Figure 5.1c). Each of these groups was found to be enriched for certain pathways. One group 
contains 1,440 genes that show an increase in gene expression at both time points with larger 
increases at 8 hours following treatment (6- to 31-fold maximum increases at 2 and 8 hours, 
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respectively). These genes show enrichment for certain pathways, such as protein folding 
(HSPA5) and localization (SEC61A1) pathways.  
We also identified expression changes in genes involved in RNA regulation. Genes that 
show increases in expression early (at two hours following tunicamycin treatment) are enriched 
for transcription factors (E2F7, ZNF135). Furthermore, genes found in RNA processing pathways 
also changed following ER stress. Specifically, splicing factors show decreased expression 
(HNRNPD) following ER stress while factors involved in decay (DCP1A) increase in expression. 
The changes in expression of genes regulating RNA led us to ask whether RNA processing, 
specifically RNA editing, may also be affect by ER stress. 
ADAR RNA editing levels following ER stress 
 First, we focused on canonical, A-to-G editing by comparing the RNA sequences to the 
reference genome (hg18) to identify sites where the RNA did not match the corresponding DNA 
sequences. In order to compare editing across individuals and across time points we required 
that the site be found in at least 10 out of the total 30 samples sequenced (which include 
before, 2 and 8 hours following ER stress in ten B-cell lines). In this way, we identified 4,020 A-
to-G editing sites, 3,023 of which are located in 739 annotated genes while the rest are found in 
intergenic regions. Of those found in annotated genes, 2,915 editing sites (96%) are located in 
non-coding regions (1,565 in introns and 1,350 in untranslated regions). As the majority of 
these sites are located in non-coding, regulatory regions, these data suggest that editing in 
these regions may affect gene expression. 
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We next asked whether ADAR editing changes under ER stress conditions. We used 
ANOVA to identify 342 sites in 185 genes whose level change following ER stress induction (p-
value <0.05) (Figure 5.2a). Though none of these 342 editing sites are significant following 
Bonferroni correction for multiple testing, we proceeded to study these 342 sites to learn about 
trends of editing that may occur following ER stress. At 2 hours after tunicamycin treatment, 
114 sites showed changes in editing levels ranging from 12-fold increase to 9-fold decrease in 
level (88 increase, 26 decrease). Following 8 hours of ER stress, 207 sites changed editing levels 
from 13-fold increase to 9-fold decrease in expression (192 increase, 15 decrease). These 
groups are not exclusive as we see 51 editing sites that change levels at both time points (post 
hoc t-test, p < 0.05). While the majority of sites show an increase in editing level at 2 hours, 
over 92% of sites show an increase in editing level following 8 hours of ER stress. This 
coordinated response suggests that a factor responding to ER stress affects the editing of these 
192 sites. 
To determine if ADAR expression was affected by ER stress, we first measured ADAR 
mRNA expression by quantitative PCR in five individuals and did not detect a significant change 
in ADAR mRNA expression following 8 hours of ER stress (Figure S5.1a). Additionally, we 
measured ADAR protein expression in two individuals and no significant change in expression 
was found following 2 or 8 hours of ER stress (Figure S5.1b). Therefore, changes in ADAR 
expression alone, do not account significantly for the changes in editing level that we see 
following ER stress. 
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Next, we analyzed the editing level changes following ER stress using hierarchical 
clustering of the 342 editing sites. These editing sites cluster into four groups that separate 
editing level patterns based on increases or decreases in editing level following 2 or 8 hours of 
ER stress (Figure 5.2a). Many of the editing sites are found in genes involved in processes 
important for ER stress response, such as protein modification and metabolism. For example, 
202 editing sites show an increase in editing level at both time points (up to about 13-fold 
increases) are found in genes involved in the protein modification (RFWD3, PRKCSH) and 
protein trafficking (SRP9, GGA1). Other sites can be found in genes involved in a variety of 
processes, such as mRNA processing (RBM3, APOBEC3D) and cell cycle control (KNTC1, DMTF1). 
These results suggest a role for ADAR editing in regulating the ER stress response. 
Validation of ADAR editing following ER stress 
As a way to validate some editing sites and better assess individual variability in editing 
level, we performed targeted RNA sequencing. We focused on 41 regions with 144 editing sites 
from the original dataset. 27 of these regions are in 3’ untranslated regions, 12 in introns, and 2 
in an intron and exon. These regions are in 38 genes involved in ER stress response or protein 
processing (Table S5.1). We sequenced the 41 target regions in 16 additional individuals before 
treatment and following 2 and 8 hours of treatment with either tunicamycin or DMSO, as a 
control.  
We obtained sequencing data for 125 A-to-G editing sites identified with the original 
dataset. Among these 118 sites were covered by at least ten sequencing reads. Of the 125 sites, 
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114 (91%) had G-containing reads in in the targeted sequencing, thus confirming the presence 
of editing at these sites.  
To study trends of RNA editing in this additional dataset, we identified RNA editing sites 
using similar criteria. A site was required to be found in 10 of the 80 samples (16 individuals 
under five conditions). We identified 207 RNA editing sites, including 150 additional A-to-G sites 
not seen in the original dataset. Though 114 sites from the original dataset showed evidence of 
editing in the targeted sequencing, only 57 were called as editing sites using our thresholds. 
Among these 207 editing sites, 11 were found to show significant changes in editing level 
following ER stress when comparing baseline editing levels to 2 and to 8 hours following ER 
stress (ANOVA, p-value < 0.05). As seen in the original dataset, 94% of sites that change in level 
show an increase in editing level following ER stress. In addition, seven sites that were found to 
be significant in the original 10 individuals were identified as editing sites in the targeted 
sequencing. Of these seven sites, three had a p-value less than 0.1 by ANOVA determining 
change in editing level following ER stress in the additional 16 individuals. One site 
(chr2:223132607) in a region 3’ of a gene SGPP2, involved in ER stress-induced autophagy 
(Lépine et al., 2011), shows significant changes in editing level in both datasets (Figure 5.2b). 
The targeted sequencing validates our initial findings of RNA editing level changes in response 
to ER stress and expands our list of responsive editing sites. 
ADAR editing and gene expression 
Editing levels across individuals are highly variable before and following induction of ER 
stress. Specifically, 37% of editing sites show greater than a 5-fold difference between the 
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maximum and the minimum editing level across the 10 individuals at baseline (38% and 35% at 
2 hours and 8 hours, respectively). In the previous chapter, my data suggest that cis variation 
may play a role in editing variability. Here, we asked whether variability in editing level could 
lead to variability in gene expression following ER stress. 
 Next, we asked whether ADAR editing levels are correlated to changes in gene 
expression following ER stress. Of the 342 editing sites that change levels following ER stress, 
101 sites are found in 76 genes that show changes in gene expression as well. We compared 
the editing level at one time point to the gene expression at the next time point to see if editing 
level may affect gene expression changes. We found 17 sites in 15 genes where the editing level 
was highly correlated to gene expression at a later time point (correlation coefficient, r > 0.632, 
p-values < 0.05). Eleven sites have baseline editing levels that are correlated with 2 hour gene 
expression levels while 7 sites have 2 hour editing levels that are correlated with 8 hour gene 
expression levels. A few examples of these correlations are shown in Figure 3. When comparing 
editing levels from baseline to gene expression at 2 hours, we found that 73% of sites (8 out of 
11) show a negative correlation. Only 42% of sites (3 out 7) show a negative correlation of 
editing level at 2 hours to gene expression at 8 hours. Furthermore, the same site may be 
correlated in opposite directions. For example, such as chr12:119383458 found in GATC (Figure 
5.3) has baseline editing level that is negatively correlated to gene expression at 2 hours but the 
editing level at 2 hours is positively correlated to gene expression at 8 hours after tunicamycin. 
This demonstrates that there can be a change in the relationship between editing level and 
gene expression following cellular stress. Furthermore, editing sites can be both positively and 
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negatively correlated to gene expression (Table S5.2) suggesting that each site may play a 
unique effect on its transcript.  
Conclusions 
ER stress response utilizes many pathways to cope with excess misfolded proteins. In 
this study, we describe how RNA editing and gene expression change in response to ER stress. 
Using high-throughput sequencing we identified over 300 editing sites that change levels 
following ER stress. Many of the editing sites can be found in genes relating to the ER stress 
response such as those involved in protein transport and protein modification. Previous reports 
of editing demonstrate that editing sites can modulate gene expression in a variety of ways, 
including affecting splicing and RNA degradation. Together, this suggests that a change in RNA 
editing level following ER stress may affect expression of genes involved in the ER stress 
response. In this way, RNA editing may play a role in the ER stress response. Another report 
suggests that lack of ADAR editing can lead to ER stress and apoptosis (Qiu et al., 2013) while 
our work demonstrates how this may be accomplished, through an effect of editing on gene 
expression. 
Furthermore, almost 90% of editing sites show an increase in editing level following ER 
stress despite only minor changes to ADAR expression level. This suggests that many of these 
editing levels may be acted upon by a factor that modifies ADAR editing. Changes in this factor 
following ER stress then lead to an increase in editing level throughout the transcriptome. This 
type of mechanism is similar to that seen in transcription factors where change in expression of 
one transcription factor can lead to changes in the expression of many genes. These data 
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suggest another way that the cell may be able to induce transcriptome-wide changes in gene 
expression during cellular stress. 
While, this is the first transcriptome-wide description of RNA-DNA Differences during a 
cellular response and demonstrates the importance of studying RNA processing changes to 
cellular stress, it is important to stress caveats in the experimental design. First, only ten 
individuals were analyzed in the main dataset and are used for comparison of gene expression 
levels and editing levels. This limited sample size reduces the power to detect significant 
changes in gene expression or editing levels or correlation between these two factors. 
Furthermore, each of these individuals was only measured once. Future experiments should be 
aimed at repeating the sequencing of these individuals to ensure that any variability is due to 
biological individual differences. Although further experiments should verify these results, the 
data thus far suggest that individual variation in editing level may contribute to differences in 
ER stress response. 
Methods 
Cell culture: B-cells 
Cultured B-cells from 26 unrelated individuals from the CEPH-Utah collection were used 
(GM07000, GM10838, GM10839, GM11992, GM11993, GM11994, GM12716, GM12717, 
GM12877, GM12878, GM10842, GM10843, GM12752, GM12753, GM12864, GM12865, 
GM10836, GM10837, GM10852, GM10857, GM12766, GM12767, GM10830, GM10831, 
GM10846, and GM10847). B-cells were cultured at a density of 5 x 105 cells/mL in RPMI 1640 
with 15% fetal bovine serum, 100 units/mL penicillin-streptomycin and 2mM L-glutamine.  
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Induction of ER Stress 
To induce ER stress, we treated the cells with 4 µg/mL tunicamycin (Sigma-Aldrich) in 
DMSO. Control cultures were grown in media as described above with 0.5% DMSO. Samples 
were collected at indicated time points (before treatment, 2, 8, 12, 24, 36, or 48 hours after 
treatment). To validate ER stress, we assayed for x box-binding protein 1 (XBP1) splicing via PCR 
resolved by a 2% agarose gel. The following primers were used: forward, 5’-
GCTGAAGAGGAGGCGGAAG-3’; reverse, 5’-GTCCAGAATGCCCAACAGG-3’. Protein expression of 
BiP was assessed via western blot (Cell Signaling #3177). Western blot was also probed with 
antibody specific for GAPDH as a loading control (Santa Cruz sc-137179). 
RNA-sequencing and analysis of ten individuals 
RNA-seq of 30 samples was performed as recommended by the manufacturer (Illumina). 
The 30 samples are comprised of B-cells from 10 individuals (GM07000, GM10838, GM10839, 
GM11992, GM11993, GM11994, GM12716, GM12717, GM12877, and GM12878) with RNA 
extracted from three time points each: before treatment and two and eight hours following 
tunicamycin treatment. RNA was extracted from the cultured B-cells using Qiagen RNeasy 
purification kits. The quality of the RNA was measured using the BioAnalyzer and only those 
with RIN > 9.0 were used in this study. cDNA was made using Illumina TruSeq library 
construction kits. Briefly, RNA was first denatured, then fragmented and first and second strand 
synthesis was performed using oligo-dT primers. Adapters were added to the cDNA and 
samples were PCR amplified. The libraries were sequenced on a Hi-Seq instrument (Illumina, 
San Diego, USA). 
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The resulting sequences were analyzed as follows. Low quality bases (Phred-scale ≤2) at 
the 3’ ends of reads were trimmed prior to alignment of the reads to the human reference 
genome (hg18) using GSNAP (version 2012.01.11, Wu and Nacu, 2010). The following 
parameters were used for mapping: number of mismatches ≤ [(read length+2)/12-2], mapping 
score ≥ 20, soft-clipping on (trim mismatch score = -3), known exon-exon junctions as defined 
by RefSeq, Gencode (version 3c) and novel junctions as defined by GSNAP. SNP tolerant 
alignment was used with SNPs from the CEU population of HapMap (International HapMap 
Consortium 2003, release #28) and 1000 genomes (1000 Genomes Project Consortium, pilot 
project). Reads that aligned to only one genomic location were used. Gene expression was 
quantified using Cufflinks v2.1.1. A gene is considered “expressed” if at least five of the 30 
samples had an FPKM ≥ 1. 
Targeted RNA-sequencing and Analysis 
Targeted RNA-seq of 16 individuals (GM10842, GM10843, GM12752, GM12753, 
GM12864, GM12865, GM10836, GM10837, GM10852, GM10857, GM12766, GM12767, 
GM10830, GM10831, GM10846, and GM10847) was performed using the TruSeq Custom 
Amplicon Library preparation (Illumina) in conjunction with Maxima H Minus Double-Stranded 
cDNA Synthesis Kit (Thermo Scientific). Briefly, RNA was reverse transcribed to cDNA using 
oligo-dT primers. A second strand of cDNA was synthesized and the resulting double-stranded 
cDNA was then purified (QIAGEN). The double-stranded cDNA was then used for the TruSeq 
Custom Amplicon kit (Illumina). This protocol entailed hybridization of 2 probes unique to a 
given target (82 total targets), extension and ligation of DNA complementary to the sample, 
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addition of indices and adapters. This was performed on 96 samples which were then multi-
plexed on a MiSeq sequencer (property of Hudson Alpha, Huntsville, Alabama) to produce 
250bp, paired-end reads. Probes were designed to 82 regions of genes involved in ER and Golgi 
function that contained A-to-G editing sites.  
The resulting reads were aligned to the targeted sequences from the human reference 
genome (hg18) using GSNAP. The number of mismatches allowed was less than or equal to 
[(read length+2)/12-2].  
DNA-sequencing and Analysis 
DNA-seq of 4 of the 10 individuals (GM10838, GM10839, GM12877, and GM12878) was 
performed as recommended by the manufacturer (Illumina). DNA was extracted from cultured 
B-cells followed by preparation of DNA-sequencing libraries using the Illumina TruSeq Paired-
End construction kits. Briefly, DNA is fragmented, adapters are ligated onto each fragment and 
fragments are amplified via PCR. The libraries were sequenced on a HiSeq instrument to 
generate paired-end 100bp reads. 
Low quality bases at the 3’ ends of reads were trimmed. The resulting reads were 
aligned to the human reference genome (hg18) using GSNAP. The following parameters were 
used for mapping: number of mismatches ≤ [(read length+2)/12-2], mapping score ≥ 20, and 
soft-clipping on (trim mismatch score = -3). SNP sites found in dbSNP and 1000 genomes were 
included for SNP-tolerant alignments. Reads that aligned to only one genomic location were 
used. 
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Identifying RNA editing sites 
To identify RNA editing sites we compared the RNA-sequencing reads to the reference 
human genome (hg18). To be included as an RNA editing site for a given sample, a site had to 
pass multiple criteria: 1) 10 total reads from RNA-seq, 2) 2 G-containing reads (5% of the total 
reads at position), 3) if within an intron, the site must be greater than 10 base pairs from the 
intron-exon junction, 5) site is not considered a SNP by dbSNP (build 138), 1000 genomes or the 
Exome Sequencing Project, and 6) no G-containing read is found in any of the 4 DNA samples. 
Additionally, the final list comprises of sites that are found in at least 10 out of the 30 samples 
whose RNA was sequenced. 
In order to ensure uniqueness of RNA editing sites, further filtering steps were 
implemented. All sites found in pseudogenes (as annotated by RefSeq) and repetitive regions 
(RepeatMasker) except Alu elements were removed. Next, the genomic regions around each 
site (in 25bp, 50bp and 75bp each direction) must be unique as determined by mapping with 
local sequence alignment (BLAT). Sites were removed if BLAT revealed an alternative alignment 
with 3 or fewer mismatches. To ensure accurate mapping of RNA-sequencing reads, each read 
containing the RDD/edited form of the transcript was aligned using a local sequence aligner 
(BLAT). For a site to be included, over 50% of the RDD/edited reads must align to the same 
position with BLAT as with GSNAP. 
To ensure that the genomic sequence is homozygous across individuals, we used 
sequencing data from 99 CEU individuals (the same population as the 10 in our dataset) in the 
1000 Genomes collection. We identified sites that have at least 10 reads across all individuals 
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and 99% of the reads containing the reference base (to allow for sequencing error at such great 
sequencing depths). We also required that all of the DNA sequences contain the reference base 
if covered by the DNA-sequencing of four individuals (as described above). 
ADAR Protein Expression Level 
 Quantitative PCR was used to detect RNA expression of ADAR (Forward: 5’- 
GGTAGAGAAGGCTACGTGGTG, Reverse: 5’- CGGGTCTTGCACTTCCTC). A housekeeping gene, 
NDUF4A, was used as a control (Forward: 5’- GTCAGGCCAAGAAGCATCC, Reverse: 5’- 
GCTCCAGTAGCTCCAGTTCC). Protein expression of ADAR was assessed via western blot (Sigma 
HPA003890). Western blot was also probed with antibody specific for GAPDH as a loading 
control (Santa Cruz sc-137179). 
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Figure 5.1 
 
Figure 5.1: Gene expression changes following ER stress. A) B-cells were treated with 4µg/mL 
tunicamycin. XBP1 splicing was assessed on a 2% agarose gel before treatment (0hr), 2 and 8 hours after 
treatment with tunicamycin or vehicle, DMSO. The upper band is the unspliced form while the lower 
band is the spliced form of XBP1. The spliced form of XBP1 is increased at 2 hours following tunicamycin 
treatment. B) Protein expression of BiP was assessed via western blot using GAPDH as a loading control 
and is shown for a representative individual (GM11994). Increase in BiP protein expression is apparent 
at 8 hours following tunicamycin treatment. Gene expression of BiP was determined from ten 
individuals by RNA-sequencing. FPKM values are shown on the graph for before treatment (0hr), and 2 
and 8 hours following tunicamycin treatment. Each line represents one individual. C) Heatmap showing 
the 4,182 genes that show changes in gene expression following ER stress. Genes were clustered using 
hierarchical clustering into five groups as shown to the right. Examples of genes are listed for each 
group. Blue indicates a decrease in gene expression as compared to baseline while red correspond to 
increases in gene expression. 
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Figure 5.2 
 
Figure 5.2: Editing level changes following ER stress. A) Heatmap showing the 342 A-to-G editing sites 
that show changes in level following ER stress. Sites were clustered using hierarchical clustering into four 
groups as shown to the right. Examples from each cluster are listed. Blue indicates a decrease in level as 
compared to baseline while red shows an increase in editing level. B) Editing level for three sites are 
graphed (chr2:223132607 downstream of SGPP2, chr2:37181094 downstream of EIF2AK2, and 
chr1:224041268 in SRP9). Editing levels are shown for three time points: baseline (0hr) in blue, 2 hours 
after tunicamycin treatment in red and 8 hours after tunicamycin treatment in green. Solid circles 
denote editing levels of ten individuals while hollow circles indicate editing levels at the same site from 
the 16 individuals from the targeted sequencing. Each point shows the editing level of one individual. 
Black line indicates the average of each group. 
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Figure 5.3 
 
Figure 5.3: Editing level and gene expression following ER stress. Graphs depicting the correlation of 
editing levels at three sites compared to gene expression at the following time point (chrX:100241566 in 
CENPI, chr12:119383458 in GATC, and chr10:70190507 in CCAR1). Hollow circles depict baseline editing 
level compared to gene expression at 2 hours following tunicamycin treatment. Solid circles indicate 
editing level 2 hours following tunicamycin treatment compared to gene expression 8 hours following 
tunicamycin treatment. In each graph, data from each individual are represented as dots. 
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Table S5.1: Regions for targeted sequencing. 
Chromosome Begin Position End Position Gene Name 
chr1 6205582 6206131 ICMT 
chr1 38099203 38099705 INPP5B 
chr1 177309321 177309822 FAM20B 
chr1 177593282 177593811 SOAT1 
chr1 224040924 224041425 SRP9 
chr2 24077228 24077729 UBXN2A 
chr2 32387609 32389540 YIPF4 
chr2 37180818 37181896 EIF2AK2 
chr2 37182498 37182998 EIF2AK2 
chr2 37184420 37184919 EIF2AK2 
chr2 223132510 223133010 SGPP2 
chr3 10167622 10168421 VHL 
chr3 157741721 157742259 SSR3 
chr3 197563406 197563919 UBXN7 
chr4 177489112 177489616 SPCS3 
chr5 34988582 34989114 DNAJC21 
chr5 74709176 74709679 COL4A3BP 
chr5 138646161 138646661 MATR3 
chr6 43018756 43019275 CNPY3 
chr7 44808215 44808743 PPIA 
chr7 56113957 56114473 SUMF2 
chr8 42995016 42995515 HOOK3 
chr8 98809764 98810275 MTDH 
chr9 138455144 138456005 SEC16A 
chr11 31409531 31410070 DNAJC24 
chr11 61373634 61374183 FADS2 
chr12 97652638 97653167 APAF1 
chr14 52311891 52312399 GNPNAT1 
chr15 72106716 72107226 PML 
chr16 23383814 23384323 GGA2 
chr16 55531587 55532113 HERPUD1 
chr16 68847596 68848108 AARS 
chr17 4868795 4869294 KIF1C 
chr17 4871577 4872100 KIF1C 
chr17 40232423 40232923 GJC1 
chr17 73930091 73930617 PGS1 
chr17 77138910 77139442 NPLOC4 
chr19 1409253 1409765 APC2 
chr19 12912805 12913332 CALR 
chr21 41741431 41741964 MX1 
chr22 35213724 35214224 FOXRED2 
Table S5.1: Chromosome position is based on hg18. 
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Table S5.2: Correlation of editing level and gene expression. 
Chromosome Position Gene Name 
r (baseline 
editing, 2hr 
expression) 
r (2hr editing, 
8hr 
expression) 
1 6633172 DNAJC11 0.02 0.77 
1 10443352 DFFA 0.64 0.12 
2 171886747 METTL8 0.71 0.09 
3 40553935 ZNF621 0.77 0.17 
5 74709587 COL4A3BP 0.07 0.76 
5 74710652 COL4A3BP 0.72 0.03 
5 138646437 MATR3 0.38 0.66 
7 86653592 DMTF1 0.84 0.39 
10 70189946 CCAR1 0.70 0.55 
10 70190507 CCAR1 0.76 0.18 
12 119383458 GATC 0.64 0.77 
12 131807977 PGAM5 0.65 0.12 
16 73256026 RFWD3 0.29 0.94 
16 88143470 SPG7 0.13 0.65 
17 23959638 SGK494 0.71 0.23 
19 63046245 LOC100293516 0.59 0.72 
X 100241566 CENPI 0.81 0.63 
Table S5.2: Correlation coefficient denoted by “r”.  
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Figure S5.1 
 
Figure S5.1: ADAR expression under ER stress conditions. A) Quantitative PCR of ADAR expression across 
five individuals (GM07345, GM11993, GM11994, GM12044, GM12716) before and following 8 hours of 
tunicamycin treatment. There is not a significant change in expression (p-value > 0.05). B) Protein 
expression of ADAR was assessed via western blot using GAPDH as a loading control. Western blot 
shown for a representative example (GM11993). 
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Chapter 6: Conclusion 
 
Summary of Findings 
 My study describes RNA editing and RNA-DNA sequence Differences (RDD) in human B-
cells and how these processes may play a role within the cell. While there had been a few 
previous reports demonstrating a non-canonical single-base difference between the RNA and 
DNA sequence (Sharma et al., 1994, van Leeuwen et al., 1998, Klimek-Tomczak et al., 2006, 
Grohmann et al., 2010), the Cheung lab was the first to identify these RDDs transcriptome-
wide. Since our first paper in 2011, many other groups have also identified RDDs (Ju et al., 
2011, Li et al., 2011, Alon et al., 2012, Silberberg et al., 2012, Vesely et al., 2012, Peng et al., 
2012, Chen 2013, Lagarrigue et al., 2013). We and others have found that RDDs can be 
translated into proteins and some are predicted to affect protein function (Sharma et al., 1994, 
Bar-Yaacov et al., 2013, Wang et al., 2013, Zhu et al., 2014).  
The mechanism leading to RDDs was still elusive so next we determined when RDDs are 
formed during transcription. The Cheung lab found that RDDs occur soon after RNA transcripts 
exit the RNA polymerase (Wang et al., 2014). This demonstrates that RDDs are not inserted 
during the process of polymerase elongation but instead, RDDs are mediated through a process 
that closely follows the polymerase. Furthermore, the Cheung lab found that individuals with a 
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mutation causing Amyotrophic Lateral Sclerosis 4 resolve R-loops more efficiently and therefore 
have fewer R-loops and fewer RDDs (Wang et al., 2013). Together, these studies determine the 
frequencies of RNA editing and RDD occur as well as bring us closer to understanding the 
mechanism of RDD formation.   
 In addition to my study of RNA-DNA Differences, I also studied canonical, ADAR-
mediated A-to-G editing in human B-cells. Previous studies had reported that ADAR enzymes 
preferentially edit adenosines in double-stranded RNA structures with no guanosine at the base 
5’ but with a guanosine at the base 3’ to the target site (Polson and Bass, 1994, Lehmann and 
Bass, 2000). My work has expanded upon this knowledge to demonstrate that genomic 
variation can affect editing across individuals. Specifically, I identified 11 A-to-G editing sites 
whose levels were associated with alleles of nearby SNPs. Though we have found these 
associations, further work will be needed to determine the causative SNP that affects editing 
level. Thus far, my work suggests that genetic variation may play a role in the individual 
differences we have seen in editing levels. 
Furthermore, I was able to use variability in editing levels across individuals to learn 
about the mode by which ADAR edits multiple sites within a long double-stranded RNA region. I 
determined that correlation of editing levels was stronger for sites within the same gene and 
within the same Alu element. Previous work has demonstrated that Alu elements often pair to 
form a double-stranded RNA structure that is can be targeted by ADAR enzymes (Athanasiadis 
et al., 2004, Bazak et al., 2014b). Therefore, my results suggest that ADAR deaminates 
adenosines on one side of a double-stranded structure at a time.  
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 In addition to studying RNA editing and RDDs at baseline, I also studied the role of RNA 
editing in the endoplasmic reticulum (ER) stress response. We found over 300 sites that showed 
changes in editing level following ER stress. Almost 90% of editing sites that changed level 
following ER stress show an increase in editing level. In addition, over 100 editing sites that 
change level are found within genes that change expression following ER stress. Of these, 17 
sites are correlated with changes in gene expression suggesting that editing may play a role in 
the gene expression changes occurring in the ER stress response. This work suggests that RNA 
editing and RDD may play a role in the ER stress response through an effect on gene expression. 
 Finally, I have studied the RNA editing of a particular site in the 3’ UTR of SEC16A, a gene 
involved in protein trafficking from the ER to the Golgi apparatus (Watson et al., 2006). The 
edited form of SEC16A is preferentially bound by HuR suggesting that editing may play a role in 
transcript stability. If this is found to be the case, then editing of SEC16A would be an example 
of how variability in editing level may affect gene expression. Further studies will help to 
illuminate the role of editing in this transcript and others.  
Significance 
 There is a large amount of phenotypic variation across many traits, from height to blood 
pressure. Some of these individual differences can be attributed to genetic variation seen in the 
DNA (Knoblauch et al., 2002, Rost et al., 2004, Tishkoff et al., 2007, Soranzo et al., 2009, 
CARDIoGRAMplusC4D Consortium 2013). However, there are many traits that we have not 
been able to map to a specific location in the genome. My work suggests that there is another 
form of variation, that seen in the RNA, that may be affecting these various traits. Through 
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work in the Cheung lab, we have identified ADAR-mediated RNA editing and non-canonical 
RDDs that show varying levels across individuals (Li et al., 2011). We have also shown that RDDs 
can be translated into proteins (Li et al., 2011) and that RNA editing in SEC16A can influence 
transcript stability. These data suggest that variability in RNA editing and RDD may affect 
cellular phenotypes that are not attributed to genetic variation in the DNA. 
In addition, RNA editing and RNA-DNA sequence differences can help us to understand 
various phases of RNA processing. Previous studies have shown that canonical RNA editing can 
affect splicing, translation and mRNA decay (Rueter et al., 1999, Zhang and Carmichael 2001, 
Scadden 2005, Lev-Maor et al., 2007). Our work demonstrates that RDDs may be linked to R-
loop formation as well (Wang et al., 2013). These works suggest that RNA editing and RDDs are 
coupled with several RNA processing steps. Therefore, the differences in editing and RDD 
across individuals and following ER stress could help to explain differences variability in gene 
expression.  
On-going Work 
 As noted in Chapter 4, I began to study an editing site in the 3’UTR of a gene, SEC16A. 
Previous work from our lab indicated that the editing of this site was mediated by ADAR1 
(Wang et al., 2013). Further data that I collected showed that when transcription was halted 
using actinomycin, the remaining transcripts of SEC16A showed an increase in the percentage 
of editing over time (Figure 4.4).  
These data suggest two different scenarios: As RNA is decayed (and not replenished due 
to the actinomycin treatment), 1) only the most stable transcripts are left at the later time 
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points suggesting that the edited transcript is more stable or 2) ADAR is continuing to edit the 
remaining RNA such that by the later time points, most of the SEC16A RNA transcripts are 
edited.  
 Previous work from our lab demonstrates that ADAR interacts with HuR, an RNA-binding 
protein1, to regulate transcript stability2. To study this further, I performed an RNA-
immunoprecipitation and found that HuR binds preferentially to the edited transcript of SEC16A 
(Figure 4.4). Furthermore, data from the lab demonstrates that editing level is lower in cells 
depleted of HuR (7% editing versus 12% editing in control samples). Together, these data 
suggest that scenario 1 may be the cause of the increase in editing level following actinomycin 
treatment.  
 In order to follow-up on these results, I treated cells with siRNA designed to knock-down 
ADAR1 and HuR to study whether the edited transcript is more stable or if the increase in 
editing level following actinomycin treatment was due to additional ADAR editing. In this 
experiment, there were 15 samples (5 knock-downs: no siRNA, non-target siRNA, ADAR1 siRNA, 
HuR siRNA and ADAR1 and HuR siRNAs together) under 3 conditions (no treatment, 
actinomycin treatment, and DMSO [vehicle] treatment for 12 hours). 
 First, I validated that ADAR1 expression was reduced in their respective samples (Figure 
6.1a,c). I verified that ADAR1 editing activity was also reduced by studying an ADAR1 target, 
PPIA (Figure 6.1d). Next, I studied the changes in editing level of SEC16A in ADAR1 knock-down 
samples following actinomycin treatment. Using ddPCR to quantify editing level of SEC16A, I 
found an initial decrease in editing level of SEC16A following ADAR1 knock-down. Under 
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actinomycin treatment, I still saw an increase in editing level. As ADAR1 protein is reduced by 
greater than 80% by siRNA treatment, these data suggest that the increase in editing level 
following actinomycin treatment is not solely due to additional ADAR1 editing. 
 This led us to the effect of HuR on changes in editing level following actinomycin 
treatment. I tried 2 different siRNAs designed to knock-down HuR. One siRNA worked more 
efficiently to knock-down HuR expression and so “HuR 1” was used for the follow-up 
experiments. Using HuR 1, I found that while HuR was not effectively knocked-down at the RNA 
level, at the protein level we found a 50% decrease in expression (Figure 6.1b,c). However, 
while our knock-down of HuR was moderately effective without additional treatment, 
actinomycin led to an increase in HuR protein expression such that the protein was only 
knocked-down 25% (Figure 6.1c). This increase in HuR expression with actinomycin treatment 
led to difficulty in validating loss of HuR activity under these conditions. We found that one 
target gene, H1F0, did show a decrease in transcript stability following HuR knock-down 
suggesting that the HuR knock-down was sufficient (Figure 6.1e). I, therefore, continued by 
studying the editing of SEC16A under these conditions. Following actinomycin treatment and 
HuR knock-down I still saw an increase in editing level of SEC16A suggesting that HuR is not 
solely responsible for this change with the caveat being that HuR expression is not completely 
suppressed. 
Future Directions 
 My thesis describes the role and regulation of RNA editing and RNA-DNA sequence 
Differences. The first identified examples of RNA editing were in select genes (Sommer 1991, 
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Köhler 1993, Nutt 1994, Burns 1997). Advances in technology, namely the development of high-
throughput sequencing technology, has allowed for the study of RNA editing throughout the 
entire transcriptome. This has led to the detection of thousands of RNA editing and RDD sites in 
humans and in other organisms (Athanasiadis et al., 2004, Levanon et al., 2004, Li et al., 2009, 
Bazak et al., 2014a, Wang et al., 2013). My thesis and the work of others in the Cheung lab has 
helped us to understand the regulation of these sites and why they may be important. 
 I have found that editing and RDD levels change for over 300 sites following ER stress. 
An increase in editing has previously been characterized for a different environmental state, 
viral infection. When a cell is invaded by an RNA virus, it promotes the interferon response. This 
induces an isoform of ADAR that then edits the virus in an attempt to destroy the virus’s 
genetic information (Patterson and Samuel, 1995, Liu et al., 1997). While the goal of editing a 
virus is to make mistakes and create mismatches, the role of changes in editing in the host 
system is less clear when found under ER stress conditions. My work suggests that the changes 
in editing levels may affect the cellular response to stress through their influence on gene 
expression. The sites that change levels following ER stress are located in the introns and 
3’UTRs of genes involved in the ER stress response, such as protein chaperones. The intronic 
and 3’ untranslated regions of an mRNA transcript are often targets of proteins that regulate 
gene expression through multiple mechanisms, including splicing and mRNA decay. This 
suggests that editing in these regions may regulate gene expression, as in the case of SEC16A, 
of genes involved in the ER stress response. If these editing sites play a role in gene expression 
then a change in editing and RDD level at over 300 sites following ER stress may affect the 
ability of the cell to respond to the cellular stress. Future studies will be aimed at understanding 
 153 
 
the role of each editing site and how editing may influence the cellular response to stress. My 
work suggests that RNA editing may play a larger role in cellular response than previously 
thought. This work also begs the question of whether RNA editing and RDDs affect cellular 
response to other stimuli. 
 In addition to differences in editing and RDD level following ER stress, we also see 
differences in level across individuals. Some editing sites, such as those in the GluR2 gene, have 
been shown to be edited to almost 100% in every individual (Sommer et al., 1991). However, 
over 40% of editing sites in my study show variable editing levels. When we consider their 
possible effect on gene expression, as seen with SEC16A, we can see that editing may play a 
role in the previously described individual variation in gene expression (Cheung et al., 2003). 
Editing may not only be important in cellular response but may be responsible for individual 
variation that we see at baseline. While some of my work suggests that cis-factors regulate 
editing level, not all of the variation in editing level that we see can be attributed to these 
factors. As described above, editing levels can be affected by the environment making them a 
way by which genotypes and environment may interact to create a phenotype. Future studies 
of editing and RDDs at baseline and following cellular stress will be able to dissect the 
interaction of genotype and environment and their effect on editing and RDD level. Our work in 
the Cheung lab studying the regulation of RNA editing and RDD should aid in this process. 
In summary 
 RNA editing and RNA-DNA sequence Differences can be found transcriptome-wide 
across tissues and individuals. RNA editing and RDD level can be affected by cellular stress 
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conditions, genomic variation in cis and RNA secondary structure. Variability in levels may lead 
differences in gene expression and RNA stability as demonstrated by editing in SEC16A. My 
work in RNA editing and RDDs sheds light on the regulation of these processing steps and how 
they may influence cellular phenotypes. 
Methods 
Knock-down and sample analysis 
Cultured B-cell from GM11994 was cultured at a density of 5 x 105 cells/mL in RPMI 
1640 with 15% fetal bovine serum, 100 units/mL penicillin-streptomycin and 2mM L-glutamine. 
Knock-down was performed following Accell protocol (Dharmacon) using four different siRNAs. 
SiRNAs designed to target HuR were custom designed (HuR 1: 5’ – 
AAGAGGCAAUUACCAGUUUCA, HuR 2: 5’ – AAUCUUAAGUUUCGUAAGUUA) while those 
designed to target ADAR or act as a control were SmartPools (E-008630-00-0020 and D-001910-
10-20, respectively). Briefly, cells were seeded at 600,000 cells/mL with 1µM siRNA in Accell 
media for 36 hours. After 36 hours, the cells were spun and resuspended in complete media for 
24 hours. After 24 hours, cells were untreated, or treated with 5µg/mL actinomycin or vehicle, 
DMSO, and collected after an additional 12 hours. DNA, RNA and protein were extracted from 
these samples. 
Primers to detect changes in RNA expression or perform Sanger sequencing can be 
found in Table 6.1. To detect changes at the protein level, three antibodies were utilized: ADAR 
(Sigma HPA003890), HuR (Millipore 03-102) and Tubulin (Millipore 05-661).  
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Figure 6.1 
 
Figure 6.1: Effect of HuR and ADAR knock-down on editing of SEC16A. A) ADAR RNA expression 
normalized to sample treated with non-targeting siRNA. B) HuR RNA expression normalized to 
sample treated with non-targeting siRNA. C) Protein expression of ADAR and HuR using β-
Tubulin as a loading control. D) Decrease in editing level of PPIA following ADAR knock-down. E) 
Decreased stability of H1F0 transcript in samples treated with HuR siRNA as compared to non-
targeting siRNA. F) Changes in editing level in one individual (GM11994) following knock-down 
of ADAR, HuR or both and treatment with 5µg/mL actinomycin or vehicle, DMSO. Samples 
without treatment of either actinomycin or DMSO and treated with non-targeting siRNA are 
shown as a control.  
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Table 6.1: Primers for ADAR and HuR knock-down. 
Target Use Forward Reverse 
ADAR Expression GGTAGAGAAGGCTACGTGGTG CGGGTCTTGCACTTCCTC 
HuR Expression ACCTCCCTCAGAACATGACC CCAAGCTGTGTCCTGCTACT 
NDUF4A Expression GTCAGGCCAAGAAGCATCC GCTCCAGTAGCTCCAGTTCC 
H1F0 Expression TGTCCTCAAGCAGACCAAAG TGAAGGCCACTGACTTCTTG 
PPIA Sanger Seq GAACACTGTTGATGTTCTTGAGG CCTCTGCAGGGAGACTGACT 
SEC16A Sanger Seq ACCTGGCTGAATGAGTGGAG AAAATCACCCATGGTCCTCA 
Table 6.1: All primers listed from 5’ to 3’. 
 
